Oncology Books

Book SynopsisDiagnose Krebs – füreinander da sein! Dieser Ratgeber richtet sich an Paare, bei denen der Mann an Krebs erkrankt ist. Er unterstützt die Partnerin bzw. den Partner des Erkrankten und bietet Hilfe bei der Bewältigung paarbezogener Belastungen und Herausforderungen. Die Diagnose Krebs stellt das ganze Leben auf den Kopf. Jeder Lebensbereich ist betroffen, unzählige Fragen kommen auf, Perspektiven verändern sich: Werde ich wieder gesund? Was wird aus meiner Beziehung? Warum musste ich krank werden, was habe ich falsch gemacht? Auch die Angehörigen sehen sich im Spannungsfeld von eigenen Belastungen und Sorge um ihren Partner vielfach mit Problemen konfrontiert. Die erfahrenen Autoren gehen einfühlsam und sachkundig auf die konkreten Herausforderungen im Lebensalltag von Krebspatienten ein. Viele Beispiele und Übungen helfen den Lesern, die eigene Situation besser zu verstehen und einzuordnen. Table of Contents

Read more less

Book SynopsisGynaecologic oncology is one of the most important subjects in gynaecology and a very challenging field. The management of patients with gynaecological cancers is complex, as the impact of the outcome of such cancers can be critical. This handbook covers the basics of carcinogenesis and the advances in the prevention and management of all gynaecologic cancers, including breast cancer. Gynaecologic oncology has always been perceived as the most difficult subject in obstetrics and gynaecology, but this handbook proves it otherwise. The text is presented in a systematic and easy-to-understand manner and is supplemented by plenty of images and illustrations and up-to-date references from established sources. The book also introduces readers to the new FIGO 2009 staging system and will be a very useful reference for researchers and clinicians.Trade Review"This comprehensive handbook covers the essentials of gynaecological oncology. The text includes all pelvic tumours as well as breast cancer, cancer in pregnancy, and fertility-sparing possibilities. It outlines well the complications of treatment with the basics of radiotherapy and chemotherapy. This is a good book for the aspiring junior doctor to have as a guide for current clinical practice and to review before ‘that exam’. A well-worth buy!"Prof. John H. Shepherd, Royal Marsden Hospital, UK"This book presents a comprehensive collection of information on gynaecologic oncology in a systematic and easy-to-understand manner. I am convinced that students, young gynaecologists, and gynaecologic oncologists will enjoy reading this informative text."Dr. Shingo Fujii, Kitano Hospital, JapanTable of ContentsWorld Cancer Statistics and Burden of Gynae Cancer. Genes and Carcinogenesis. Cancer of Vulva. Cancer of Vagina. Screening for Cervical Cancer. Human Papillomavirus and HPV Vaccine. Management of Pre-invasive Disease of Cervix. Cancer of Cervix. Cancer of Endometrium. Uterine Sarcoma. Cancer of Fallopian tube. Cancer of Ovary (Epithelial). Ovarian Germ Cell Tumours. Ovarian Sex Cord Stromal Tumours. Gestational Trophoblastic Disease. Breast Cancer for Gynaecologic Oncologist. Gynaecologic Cancer in Pregnancy. Tumour Markers in Gynaecologic Oncology. Diagnostic Imaging in Gynaecologic Oncology. Peri-operative Care for Gynaecologic Cancer Patients. Basic Anatomy and Principles of Surgery in Gynae Oncology. Basic Principles of Radiotherapy. Basic Principles of Chemotherapy. Modulating Agents,Response Modifier and Targeted Therapy. Immunotherapy and Hormonal Therapy. Management of Long-term Side Effects of Gynae Cancer Treatment. Nutritional Support For Gynaecologic Cancer Patients. Basic Surgical Procedures in Gynaecologic Oncology. Laparoscopic and Robotic Surgery in Gynaecologic Cancers. Index.

Read more less

Book SynopsisNanomaterials have the potential to shift the paradigm for the diagnosis and treatment of many diseases, especially neoplasms, because of the intriguing behaviors associated with their unique size-/shape-influenced chemical, physical, and physiological features. Currently, there is a huge imbalance between the several nanoplatforms reported in the literature and the few ones approved for clinical applications. This disequilibrium affects, in particular, plasmonic nanomaterials, which present no approved platforms and few candidates in clinical trials. This trend can be reversed by promoting collaborations among scientists from different fields as well as by improving the multidisciplinary background of researchers interested in this area. This book is a collection of must-read peer-reviewed papers focusing on (i) the main behaviors of nanomaterials for nanomedicine, (ii) key features nanomaterials need for successful translation to the clinical setting, and (iii) market analysis of nanomaterials at the bedside or on the way. The main aim of this book is to offer a comprehensive point of view to students and researchers in order to promote the translation of new technologies to patients. It is a unique reference for advanced undergraduate- and graduate-level students of nanotechnology and researchers in materials science, nanotechnology, chemistry, biology, and medicine, especially those with an interest in cancer theranostics.Table of ContentsDetecting and Destroying Cancer Cells in More Than One Way with Noble Metals and Different Confinement Properties on the Nanoscale. Engineered Nanoparticles for Drug Delivery in Cancer Therapy. Recent Progress in Cancer Thermal Therapy Using Gold Nanoparticles. Gold Nanomaterials at Work in Biomedicine. The Nanomedicines Alliance: An Industry Perspective on Nanomedicines. Nanomedicine(s) under the Microscope. Imaging Nano–Bio Interactions in the Kidney: Toward a Better Understanding of Nanoparticle Clearance. Nanomaterials for Theranostics: Recent Advances and Future Challenges. Metabolism of Nanomaterials in vivo: Blood Circulation and Organ Clearance.

Read more less

Book SynopsisUntil the early 1960s, cancer treatment consisted of surgery and radiation therapy. Most practitioners then viewed the treatment of terminally ill cancer patients with heroic courses of chemotherapy as highly questionable. This title explores how practitioners established a style of practice, at the center of which lies the clinical cancer trial.Trade Review"This remarkable book charts the emergence of a clinical field - medical oncology - for which experimental protocols have become routinized as a form of normal practice. Cancer on Trial will make a lasting contribution to the sociology of scientific knowledge, the history of clinical practice, and the understanding of the networked basis of biomedical research." (Jeremy A. Greene, Harvard University)"

Read more less

Book SynopsisDid America try to steal Soviet cancer secrets? And how could a cancer cure turn into a biological atom bomb? This tale of scientific discovery and politics investigates the ideological wrangling and conflicts within the Cold War search for a cure for cancer.Trade Review"A fascinating and seductively accessible account of medical science in Stalin's Russia, of the quest for a cure for cancer in the context of Cold War ideology, bureaucratic infighting, and disciplinary rivalries." - Charles Rosenberg, Harvard University

Read more less

Book SynopsisIn the 1960s, University of Cincinnati radiologist Eugene Saenger infamously conducted human experiments on patients with advanced cancer to examine how total body radiation could treat the disease. Using the Saenger case as a means to reconsider cold war medical trials, this book examines the tensions at the heart of clinical studies of the time.Trade Review"What is truly original about Contested Medicine is that, by using the science studies approach applied to a specific historical case, Kutcher shows not only how ethics were constitutive of the shape of experimental work on cancer at its inception but how both of these things were mutually changed over time." - Christopher Lawrence, Wellcome Trust Centre for the History of Medicine, University College London"

Read more less

Book Synopsis

Read more less

Book SynopsisGeneral Information on Cancer Staging and End-Results Reporting.- Purposes and Principles of Cancer Staging.- Cancer Survival Analysis.- Head and Neck.- Lip and Oral Cavity.- Pharynx.- Larynx.- Nasal Cavity and Paranasal Sinuses.- Major Salivary Glands.- Thyroid.- Mucosal Melanoma of the Head and Neck.- Digestive System.- Esophagus and Esophagogastric Junction.- Stomach.- Small Intestine.- Colon and Rectum.- Anus.- Gastrointestinal Stromal Tumor.- Neuroendocrine Tumors.- Liver.- Intrahepatic Bile Ducts.- Gallbladder.- Perihilar Bile Ducts.- Distal Bile Duct.- Ampulla of Vater.- Exocrine and Endocrine Pancreas.- Thorax.- Lung.- Pleural Mesothelioma.- Musculoskeletal Sites.- Bone.- Soft Tissue Sarcoma.- Skin.- Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas.- Merkel Cell Carcinoma.- Melanoma of the Skin.- Breast.- Breast.- Gynecologic Sites.- Vulva.- Vagina.- Cervix Uteri.- Corpus Uteri.- Ovary and Primary Peritoneal Carcinoma.- Fallopian Tube.- Gestational Trophoblastic Tumors.- Genitourinary Sites.- Penis.- Prostate.- Testis.- Kidney.- Renal Pelvis and Ureter.- Urinary Bladder.- Urethra.- Adrenal.- Ophthalmic Sites.- Carcinoma of the Eyelid.- Carcinoma of the Conjunctiva.- Malignant Melanoma of the Conjunctiva.- Malignant Melanoma of the Uvea.- Retinoblastoma.- Carcinoma of the Lacrimal Gland.- Sarcoma of the Orbit.- Ocular Adnexal Lymphoma.- Central Nervous System.- Brain and Spinal Cord.- Lymphoid Neoplasms.- Lymphoid Neoplasms.Trade ReviewFrom the reviews of the seventh edition:“Provide a new organ-specific classification that oncologists and other professionals who manage patients with cancer need in order to accurately classify tumours for staging. … a ‘Bible’ for oncologists, pathologists and surgeons, being also useful for all health officers, including general physicians and students, who want to remain updated in oncology. … this is a book that has to be present in all diagnostic imaging departments, as a major support to produce information adequate to the new oncology algorithms.”­­­ (Vincenzo Cuccurullo and Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, 2011)Table of ContentsGeneral Information on Cancer Staging and End-Results Reporting.- Purposes and Principles of Cancer Staging.- Cancer Survival Analysis.- Head and Neck.- Lip and Oral Cavity.- Pharynx.- Larynx.- Nasal Cavity and Paranasal Sinuses.- Major Salivary Glands.- Thyroid.- Mucosal Melanoma of the Head and Neck.- Digestive System.- Esophagus and Esophagogastric Junction.- Stomach.- Small Intestine.- Colon and Rectum.- Anus.- Gastrointestinal Stromal Tumor.- Neuroendocrine Tumors.- Liver.- Intrahepatic Bile Ducts.- Gallbladder.- Perihilar Bile Ducts.- Distal Bile Duct.- Ampulla of Vater.- Exocrine and Endocrine Pancreas.- Thorax.- Lung.- Pleural Mesothelioma.- Musculoskeletal Sites.- Bone.- Soft Tissue Sarcoma.- Skin.- Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas.- Merkel Cell Carcinoma.- Melanoma of the Skin.- Breast.- Breast.- Gynecologic Sites.- Vulva.- Vagina.- Cervix Uteri.- Corpus Uteri.- Ovary and Primary Peritoneal Carcinoma.- Fallopian Tube.- Gestational Trophoblastic Tumors.- Genitourinary Sites.- Penis.- Prostate.- Testis.- Kidney.- Renal Pelvis and Ureter.- Urinary Bladder.- Urethra.- Adrenal.- Ophthalmic Sites.- Carcinoma of the Eyelid.- Carcinoma of the Conjunctiva.- Malignant Melanoma of the Conjunctiva.- Malignant Melanoma of the Uvea.- Retinoblastoma.- Carcinoma of the Lacrimal Gland.- Sarcoma of the Orbit.- Ocular Adnexal Lymphoma.- Central Nervous System.- Brain and Spinal Cord.- Lymphoid Neoplasms.- Lymphoid Neoplasms.

Read more less

Book SynopsisBest-selling author Pia de Jong’s vivid memoir about her daughter’s battle with leukaemia and the startling decision that led to her recovery.Trade Review"... her prose is vibrant and precise..." -- Times Literary Supplement

Read more less

Book SynopsisNow in its second edition, this is the only book on occupational therapy in oncology and palliative care. It has been thoroughly updated, contains new chapters, and like the first edition will appeal to a range of allied health professionals working with patients with a life-threatening illness.Trade Review"I would recommend this practical text to both students and professionals in the field." (British Journal of Occupational Therapy, 2007)Table of ContentsList of Contributors ix Foreword xi Derek Doyle, MD, OBE Preface xiii Acknowledgements xiv Introduction xvii 1 What is Cancer? 1 Jill Cooper 2 Challenges Faced by Occupational Therapists in Oncology and Palliative Care 11 Jill Cooper 3 Occupational Therapy Approach in Symptom Control 27 Jill Cooper 4 Occupational Therapy in Anxiety Management and Relaxation 41 Jill Cooper 5 Occupational Therapy in the Management of Breathlessness 51 Jill Cooper 6 Occupational Therapy and Cancer-Related Fatigue 61 Daniel Lowrie 7 Client-centred Approach of Occupational Therapy Programme – Case Study 83 Gemma Lindsell 8 Occupational Therapy in Paediatric Oncology and Palliative Care 107 Claire Tester 9 Occupational Therapy in HIV-related Cancers and Palliative Care 125 Will Chegwidden and Camilla Hawkins 10 Occupational Therapy in Neuro-oncology 145 Helen Barrett and Julie Watterson 11 Occupational Therapy in Hospices and Day Care 161 Anne Bostock, Shelley Ellis, Sara Mathewson and Lilias Methven 12 The Use of Creativity as a Psychodynamic Activity 175 Kathryn Boog 13 Measuring Occupational Therapy Outcomes in Cancer and Palliative Care 189 Gail Eva Appendices 201 Glossary 239 Glossary-Abbreviations 247 Index 249

Read more less

Book SynopsisThis is a comprehensive guide to cervical cancer for nurses. It is a practically-based text for clinical nurses who wish to consolidate and update their knowledge of cervical cancer. It is concise, containing comprehensive information for general practice together with useful references to facilitate more in-depth study. Thus it provides an invaluable resource for both the registered nurse with a general interest in cervical cancer and for the nurse specialist working in primary health, gynaecology, oncology and palliative care. As well as containing the essential chapters about the pathophysiology and treatment of cervical abnormalities and cervical cancer, the book also addresses specific nursing issues such as sexuality, fertility, and symptom control. Moreover it examines the bigger, global picture of the disease. Full appreciation of global impact of cervical cancer on women involves an appreciation of the social, political and public health aspects of the disease not only inTrade Review“This is a high quality book, both in content and thoroughness.” (Doody's Reviews, May 2009)Table of ContentsAcknowledgements. 1. Dysplasia, HPV and cervical cancer. 2. Pre-invasive disease, colposcopy and adenocarcinoma. 3. Surgery. 4. Radiotherapy. 5. Chemotherapy. 6. Psychological and Social Aspects of Cervical Cancer. 7. Fertility and menopause. 8. Cervical screening. 9. Cervical cancer in developing countries. 10. Cervical cancer vaccines.

Read more less

Book SynopsisWritten by a team of international experts, this book provides an authoritative overview and practical guide to the molecular biology and genetic basis of haematologic cancers including leukemia.Table of ContentsList of contributors xi Preface xiii 1 The myelodysplastic syndromes 1 Cristina Mecucci, Valeria Di Battista and Valeria Nofrini Introduction 1 Predisposing conditions 2 Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) 2 Severe congenital neutropenia (SCN) 5 Poikiloderma with neutropenia 6 Familial MDS/AML 6 Shwachman–Diamond syndrome (SDS) 7 Dyskeratosis congenita (DKC) and telomere syndromes 8 Fanconi anaemia (FA) 11 Down syndrome 12 Cytogenetics 12 Loss of Y chromosome (–Y) and del(11q) 13 Del(20q) 15 idic(X)(q13) 15 Del(17)(p13)/i(17q) 15 Del(12p) 16 Trisomy 8 16 Rare trisomies: +6, +13, +14, +15, +16, +19, +21 16 Monosomy 7 and del(7q) 17 Rare monosomies 19 Unbalanced translocations involving 1q 19 t(17;18)(p10;q10) 20 Rare or sporadic balanced translocations 20 Complex karyotypes 22 Chromosome 5q deletions 23 Somatic mutations 31 Oncogenes and tumour suppressor genes 31 Mutations of genes involved in epigenetic modulation 39 Mutations of genes involved in the spliceosome machinery 45 Rare gene mutations in myelodysplastic syndromes 48 Epigenetics 49 DNA methylation 50 Histone modifications 52 RNA 53 Conclusion 54 References 54 2 Molecular genetics of the myeloproliferative neoplasms 80 Philip A. Beer Introduction 80 Overview of the different types of mutation found in MPN patients 80 Acquired mutations in cytokine signalling pathways 82 Acquired mutations in pathways controlling transcriptional regulation 84 Acquired mutations associated with transformation to advanced-phase disease 87 Inherited predisposition to clonal MPNs 87 Inherited non-clonal disorders that phenocopy distinct MPNs 87 Polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) 88 Acquired mutations in cytokine signalling pathways (Table 2.3) 89 Acquired mutations in pathways controlling transcriptional regulation (Table 2.4) 95 Acquired mutations associated with progression to advanced and blastic-phase disease 101 Inherited predisposition to clonal MPNs 103 Inherited non-clonal disorders that phenocopy distinct MPNs 104 Principles and clinical utility of laboratory testing 107 Chronic eosinophilic leukaemia 109 Acquired mutations in cytokine signalling pathways 109 Acquired mutations in pathways controlling transcriptional regulation 113 Acquired mutations associated with progression to advanced and blastic-phase disease 113 Inherited predisposition to clonal MPNs 113 Inherited non-clonal disorders that phenocopy distinct MPNs 114 Principles and clinical utility of laboratory testing 114 Neoplastic mast cell disease 115 Acquired mutations in cytokine signalling pathways 116 Acquired mutations in pathways controlling transcriptional regulation 118 Acquired mutations associated with progression to advanced and blastic-phase disease 118 Inherited predisposition to clonal MPNs 119 Inherited non-clonal disorders that phenocopy distinct MPNs 119 Principles and clinical utility of laboratory testing 120 References 121 3 Acute myeloid leukaemia 133 Matthew L. Smith and Thomas McKerrell Introduction 133 AML classification 134 Cytogenetic aberrations 135 Fusion genes arising from structural rearrangements 135 Monosomies 148 Complex and monosomal karyotypes 148 Trisomies 148 Double minute chromosomes 151 Normal karyotype – is it really normal? 151 Altered gene expression 152 EVI1 152 BAALC 153 MN1 153 ERG 154 SET 154 BRE 154 WT1 154 miRNA genes 154 Diagnosis and classification of AML 155 Current risk stratification of AML patients: European LeukemiaNet (ELN) guidelines 156 Therapeutic regimens in AML 158 Management of younger adults aged 18–60 years 159 Older AML patients (aged >60 years) 159 Novel agents 160 Monitoring response to therapy (MRD) 160 The genomics of AML 161 Clonal evolution of AML 161 Established recurrent mutations in AML 163 Novel recurrent mutations in AML 173 Emerging concepts and future directions 179 Age-related clonal haematopoiesis (ARCH) 179 Application of genomic technologies to the diagnosis of AML 179 Conclusion 181 Mini-glossary 183 References 184 4 Molecular genetics of paediatric acute myeloid leukaemia 203 Marry van den Heuvel-Eibrink, Jasmijn D.E. de Rooij and Christian Michel Zwaan Clinical introduction 203 Epidemiology of AML 203 Diagnostic approach 204 Treatment and outcome 205 Relevant molecular and genetic aberrations in paediatric AML 206 Type I/II aberrations and their non-random associations 206 Relevance of type I/II aberrations for outcome and stratification of paediatric AML treatment 209 Epigenetic modifiers and hydroxymethylation pathway mutations 212 Further strategies 213 Further genomic approaches to unravelling the biology of paediatric AML 213 Molecularly targeted therapy 214 Conclusion 215 References 215 5 Acute lymphoblastic leukaemia 223 Anna Andersson, Anthony V. Moorman, Christine J. Harrison and Charles Mullighan Introduction 223 Chromosomal aberrations in BCP-ALL 224 High hyperdiploidy 227 t(12;21)(p13;q22)/ETV6-RUNX1 232 t(1;19)(q23;p13)/TCF3-PBX1 233 t(17;19)(q22;p13)/TCF3-HLF 234 Hypodiploidy 234 11q23/KMT2A (MLL) gene rearrangements 236 t(9;22)(q34;q11.1)/BCR-ABL1 237 Intrachromosomal amplification of chromosome 21 (iAMP21) 238 Complex karyotype 239 Submicroscopic genetic alterations in BCP-ALL 240 Alteration of transcription factors in BCP-ALL 241 CRLF2 rearrangements and Janus kinase mutations in ALL 242 BCR-ABL1-like or Ph-like ALL 243 ERG-altered ALL 245 Genetic rearrangements in T-lineage ALL 245 TAL1/LMO2 rearranged T-ALL 247 TLX1/TLX3 rearranged T-ALL 248 Early T-cell precursor ALL 249 Other T-ALL genetic subtypes: MLL rearranged and PICALM-MLLT10 250 Relapsed ALL 251 Future directions 252 References 252 6 The genetics of mature B-cell malignancies 265 Jonathan C. Strefford, Jude Fitzgibbon, Matthew J.J. Rose-Zerilli and Csaba Bödör Introduction 265 Chronic lymphocytic leukaemia 266 Immunoglobulin heavy-chain variable region gene mutational status 267 Chromosomal banding and interphase molecular cytogenetics 268 Copy number alterations 269 Deletions of 13q14 269 Trisomy 12 272 Deletions of 11q24 and mutations of ATM 273 Deletions of 17p13 and mutations of TP53 275 Other copy number alterations in CLL 276 Genome complexity and chromothripsis 277 Novel mutations in patients with CLL 279 NOTCH1 280 SF3B1 281 Other genes 282 Novel genetic mutations in clinical practice 282 Germinal centre lymphomas 284 Follicular lymphoma 286 Diffuse large B-cell lymphoma 293 Conclusions and future perspectives 296 Acknowledgements 299 References 299 7 The genetics of chronic myelogenous leukaemia 312Philippa C. May, Jamshid S. Khorashad, Mary Alikian, Danilo Perrotti and Alistair G. Reid Introduction 312 Clinical features 313 The structure and physiological function of BCR and ABL1 316 The structure of the BCR-ABL1 fusion gene 317 Mechanisms of BCR-ABL1-induced oncogenesis 319 Potential mechanisms underlying the genesis of CML 320 CML blast crisis transformation 321 Tyrosine kinase inhibitor (TKI) therapy 325 The genetic basis of TKI resistance 326 Novel therapeutic approaches 330 Genetics in patient management 332 Cytogenetic and molecular cytogenetic monitoring 332 Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) 334 BCR-ABL1 mutation analysis 337 Conclusion 338 References 339 Index 359

Read more less

Book SynopsisThis edition presents new information, treatment diagrams, techniques, and the latest data on treatment results. An overview of fundamental concepts (from biological to technical) of radiation therapy for head and neck neoplasms is followed by a brief discussion of dental care before, during, and after the therapy. The majority of the book contains site-specific coverage of strategies for managing carcinomas of the head and neck that address applied anatomy, pathology, staging, selection of treatment modalities, radiation methods, technical pointers, and current treatment data. Includes a detailed analysis comparing conventional radiation therapy with altered fractionated radiation therapy.Table of ContentsBasic Concepts of Radiation Therapy for Head and Neck Cancer. Technical Considerations of Radiation Therapy of Head and Neck Tumors. Dental Care of Patients Receiving Radiation Therapy. Principles and Practice of Altered Fractionation Radiation Therapy. Cancer of the Skin. Cancer of the Oral Cavity. Carcinoma of the Oropharynx. Carcinoma of the Hypopharynx. Carcinoma of the Larynx. Carcinoma of the Nasopharynx. Tumors of the Nasal Cavity and Paranasal Sinuses. Tumors of the Salivary Glands. Carcinoma in Cervical Node with Unknown Primary. Tumors of the Temporal Bone and Skull Base. Miscellaneous Tumors. Tumors of the Eye. Complications of Radiation Therapy. Future Prospects of Radiation Therapy for Head and Neck Tumors. Index.

Read more less

Book SynopsisPlant lectins are extensively used as tools and as bioactiveproteins in different areas of biomedical and biological research.The Handbook of Plant Lectins provides a comprehensive yet conciseoverview of the biochemical properties, carbohydrate-bindingspecificity, biological activities and applications of most of thecurrently known plant lectins. This handbook consists of two majorsections: an introductory guide and a quick reference dictionary.Part I acquaints the newcomer to the lectin field with theessential information on lectins and their importance tobiomedicine: * what are lectins? * their carbohydrate-binding specificity * effects on nutrition and immunology * use in histochemistry * application as therapeutic agents Part II lists approximately 200 lectin entries in alphabeticalorder. Each entry deals with the lectin(s) of a particular plantand provides, (where known), details of: * isolation and characterisation; * sugar binding specificity;Table of ContentsINTRODUCTION TO LECTINS. Plant Lectins: A Special Class of Plant Proteins. Plant Lectins in Mammalian Nutrition, Immunology, Metabolism and asOral Therapeutic and Immune Agents. Lectin Histochemistry in Histology and Histopathology. LECTIN CLASSIFICATION. Key to the Use of the Lectin Entries. Classification Codes. Lectin Entries. Appendices. Index.

Read more less

Book SynopsisJames DeGregori proposes a way of thinking about cancer as a disease of evolutionone in which mutated cells outcompete healthy cells in the ecosystem of the body's tissues. By tying cancer's progression to natural selection and evolved strategies for reproductive success, his theory goes far in explaining who gets cancer, when it appears, and why.Trade ReviewWith engaging prose and an authoritative review of new research, Adaptive Oncogenesis: A New Understanding of How Cancer Evolves inside Us corrects the fundamental attribution error that has focused cancer research on malignant cells and their genes. Adaptive oncogenesis, or ‘EcoOncogenesis,’ shows that the ecosystems surrounding cells are equally important, responsible for creating selection forces that speed or slow the evolution of cancer. With huge implications for prevention and treatment, this book is required reading for cancer researchers and clinicians, and a pleasure read for anyone who appreciates fascinating new science. -- Randolph Nesse, Center for Evolution and Medicine at Arizona State UniversityDeGregori’s vision of cancer as an adaptive ecosystem is insightful and cogent. Adaptive Oncogenesis: A New Understanding of How Cancer Evolves inside Us, an evolutionary explanation for the risk of cancer as we age, is a provocative and refreshing revision of the prevailing gene-centric paradigm. -- Mel Greaves, The Institute of Cancer ResearchTo understand how and why tumors progress, James DeGregori argues that we must apply evolutionary principles to cancer. This book is a seamless discussion of natural evolutionary processes, ranging from longevity in rodents to bacterial antibiotic resistance, and drawing parallels to tumorigenesis. It is a must-read for everyone who wants to understand tumor evolution. -- Kornelia Polyak, Dana-Farber Cancer InstituteTo paraphrase Dobzhansky, cancer only makes sense in the light of evolution. In Adaptive Oncogenesis: A New Understanding of How Cancer Evolves inside Us, DeGregori challenges the commonly held view that it takes time for a normal cell to mutate into a cancer cell. He makes the compelling case that the ability to select against cancer becomes weaker as an individual gets older and the odds of reproduction decline. -- Angelika Amon, Koch Institute for Integrative Cancer Research at MITAt every point in our lives, the body holds the mutations necessary to cause cancer; why then does cancer develop primarily at certain times or after specific exposures? With crisp thinking and engaging prose, James DeGregori’s surprisingly readable book argues that cancer is a disease caused by damaged tissues rather than gene mutations. The implications of this revolutionary work have the potential to change the focus of cancer research, and especially research on cancer prevention, with emphasis on using the body’s own calculus of natural selection to keep cancers in check. -- Garth Sundem, author of Brain Trust: 93 Top Scientists Reveal Lab-Tested Secrets to Surfing, Dating, Dieting, Gambling, Growing Man-Eating Plants, and More!Adaptive Oncogenesis: A New Understanding of How Cancer Evolves inside Us is a highly readable and entertaining book, offering a fascinating new look at cancer through an evolutionary and ecological lens. With novel insights and thoughtful observations, James DeGregori guides his audience through the promise of new ideas, examining novel applications of Darwin’s principles as well as modern technological advancements connected to cancer biology and treatment. -- Robert A. Gatenby, Moffitt Cancer CenterA fresh view on how cancer originates and evolves, challenging the mutation-centric dogma of cancer genesis…An important book, accessible to general readers, teachers, and nonexpert biologists, and a must read for medical doctors and drug developers aiming to design effective cancer therapies, as it introduces the fundamental concept of evolution and tissue homeostasis into therapy design. -- Miguel Costa Coelho * Quarterly Review of Biology *

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisIn this unsettling analysis of the breast cancer movement in Canada, health activist, scholar, award-winning journalist, and cancer survivor Sharon Batt investigates the changing relationship between patient advocacy groups and the pharmaceutical industry, as well as the contentious role of pharma funding.Trade Review[Health Advocacy Inc.] expands the conversation into new terrain, exploring how industry infiltrates patient advocacy groups employing the same tools that have been so successful with doctors… -- Anne Kingston * Literary Review of Canada *Batt`s scholarly approach allows opposing voices ... [her] goal is to start a conversation and encourage discussion. She readily achieves this effect, and any cancer charity currently facing a funding dilemma would be well served by her book. -- Isabel Lokody * Lancet Oncology *Health Advocacy Inc. occasionally feels like a Russian novel. It has plot twists and dissidents whose tactics and rebellions against drug companies are nothing short of heroic. Yet Batt eschews sensational tropes about the evils of big pharma in favour of interviews and archives describing the gradual demise of the breast cancer movement. -- Deborah Ostrovsky * Herizons *Batt makes a powerful case ... To this reviewer’s knowledge, this is the only study tracking the process of neoliberal reform and its cumulative impact on the same groups within civil society over such a long time frame and is ground breaking for that reason alone. -- Nick Acheson, University of Dublin Trinity College * Voluntary Sector Review *[Batt’s] superb new book is a deep scholarly account of the way that pharmaceutical funding has warped the patient advocacy movement into a tool for medical capitalism ... Few writers are better placed to document this story ... Would-be rebels and reformers should take to heart the cautionary lessons of Health Advocacy, Inc. -- Carl Elliott * Hastings Center Report *Batt’s revelations about the relationship between patient advocacy groups and the pharmaceutical industry are vital and disturbing. -- Lisa Cumming * Maisonneuve *In sum, Batt’s is a terrific book, a focused study of a policy area that has many lessons for all concerned with effective democratic policy making and the consequences of public-private partnerships and donor influence. -- Peregrine Schwartz-Shea, University of Utah * Journal of Empirical Research on Human Research Ethics *Health Advocacy Inc. is an extremely stimulating and timely book benefitting from the author’s scholarly skills, but also from her particular standpoint as a breast cancer activist. -- Grazia De Michele, doctoral researcher in history at the University of Genoa * Somatosphere *Batt has written a compassionate account of the debates among breast cancer activists in Canada and internationally about whether to accept money from the pharmaceutical industry … Now more than ever we need advocates who put drug safety, effectiveness and affordability above the interests of pharma. -- Colleen Fuller, cofounder of Pharma Watch Canada * Alberta Views *[Health Advocacy, Inc.] is not an easy read, but it should be devoured by anyone, from any nation, who wants to put together a similarly formidable argument for transparent and genuine discussion about what we should – indeed, must – do differently to prevent and treat human suffering and disease. -- Nancy MP King, Wake Forest University * Indian Journal of Medical Ethics Online *What makes the book stand out from the rest of the vast literature on these dynamics is the wealth of personal vignettes and in-depth case studies… Academics, funders, policy researchers and campaigners of all political stripes will find a lot to like, learn and think about in this meticulously researched and well-written book. -- Till Bruckner, founder of TranspariMED and advocacy manager for Transparify * On Think Tanks *To Batt’s credit, she never falls into the partisan trap of framing the issue as a moralistic struggle of good versus evil. While she stakes out a strong position, she treats the topic with the nuance it deserves. Drawing on a wealth of ethnographic material, she chronicles how decent people and committed organisations struggled to support and represent breast cancer patients over many years, despite financial constraints and funder attempts at co-optation. -- Till Bruckner * The HealthWatch Newsletter *Table of ContentsPrefaceIntroduction: The Secret War among Patient Groups Part 1: Canada’s Health Care System Transformed – Neoliberalism and the Erosion of the Welfare State1 Canada’s Health Policy Landscape2 Health Advocacy Organizations in Canada Part 2: From Grassroots to Contestation to Partnership – The Breast Cancer Movement and Big Pharma 3 Beginnings of the Breast Cancer Movement 4 Advocacy Redefined 5 The Movement Fractures over Pharma Funding6 Pharma Funding as the New Norm7 Advocacy Groups and the Continuing Struggle over the Pharma-Funding Question Conclusion: The Fight for Medicine’s SoulAppendix: Organizations and Their MembersNotesIndex

Read more less

Book SynopsisDiscusses breast cancer in men and women, including statistics, prevention, symptoms, causes, treatments, and more. This book provides an in-depth look at the diagnostic processes associated with breast cancer, as well as relevant health information, drugs and procedures, warning signs, and more, to better help those affected by this disease.

Read more less

Book SynopsisTable of ContentsChapter 1 Diagnosis: news Chapter2 Surgery: measure Chapter 3 Chemotherapy: feelings Chapter4 Radiation: story coda Called Back: the voyage out Afterword to the 2021 Edition

Read more less

Book Synopsis Bioconductor’s Computational Ecosystem for Genomic Data Science in Cancer.- Informatics Workflows for scalable data analysis: an RNA sequencing tutorial.- Using the Cancer Epitope Database and Analysis Resource (CEDAR).- Quantifying the Prevalence of Non-B DNA Motifs as a Marker of Non-B Burden in Cancer using NBBC.- Starfish: deciphering complex genomic rearrangement signatures across human cancers.- Using FFPEsig to remove formalin-induced artefacts and characterise mutational signatures in cancer.- Inferring phenotypes of copy number clones in cancer populations using TreeAlign.- Inference of genetic ancestry from cancer-derived molecular data with RAIDS.- Pruning-assisted modeling of network graph connectivity from spatial transcriptomic data.- Inferring metabolic flux from gene-expression data using METAFlux.- Functional Pathway Inference Analysis (FPIA).- NGP: a tool to detect noncoding RNA-gene regulatory pairs from expression data.- MODIG: An Attention Mechanism-based Approach for Cancer Driver Gene Identification.- Predictive modeling of anti-cancer drug sensitivity using REFINED CNN.- Anti-cancer monotherapy and polytherapy drug response prediction using deep learning: guidelines and best practices.- Identification of somatic variants in cancer genomes from tissue and liquid biopsy samples.- SUMMER: a practical tool for identifying factors and biomarkers associated with pan-cancer survival.- Predicting tumor antigens using the LENS workflow through RAFT.

Read more less

Book SynopsisLung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. This book provides the research in the identification of biomarkers to predict a high risk for developing lung cancer.Trade Review“With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.” (Kingbook73's Medical Ebook and Video Collection, 19 September 2014) Table of ContentsContributors, viii Preface, xiii 1 Smoking Prevention and Cessation, 1Alexander V. Prokhorov and Karen Suchanek Hudmon 2 Lung Cancer Susceptibility and Risk Assessment Models, 25Xifeng Wu, Xia Pu, and Jie Lin 3 Molecular Profiling, 48Lauren Averett Byers 4 Somatic Genome Alterations in Human Lung Cancers, 67Marcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson 5 Serum Proteomic Biomarkers, 90Mohamed Hassanein and David P. Carbone 6 Molecular Biology of Lung Preneoplasia, 110Humam Kadara and Ignacio I. Wistuba 7 Detection and Treatment of Preneoplastic Lesions, 129Rachel Jen and Stephen Lam 8 Pathology of Adenocarcinoma, 144William D. Travis 9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158Howard West 10 Radiology and Lung Cancer Screening, 176Patricia de Groot and Reginald F. Munden 11 Imaging Lung Cancer, 191Sonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus 12 Staging of the Mediastinum, 202Mauricio Pipkin and Shaf Keshavjee 13 Management of the Solitary Pulmonary Nodule, 214Min P. Kim 14 Minimally Invasive Resections for Lung Cancer, 224Shanda H. Blackmon 15 Extended Resections for Lung Cancer, 236Matthew A. Steliga and David C. Rice 16 Bronchoscopic Interventions for Lung Cancer, 253Donald R. Lazarus and George A. Eapen 17 Primary Tracheal Tumors, 267Francesco Sammartino and Paolo Macchiarini 18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278Kathryn A. Gold 19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290Christopher G. Azzoli and Katherine M.W. Pisters 20 Image-Guided Radiation Therapy, 309Kenneth E. Rosenzweig and Sonal Sura 21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320Puneeth Iyengar and Robert D. Timmerman 22 Proton Therapy, 338Joe Y. Chang and James D. Cox 23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353Daniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki 24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379Heath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox 25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390Steven H. Lin and Ritsuko U. Komaki 26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406Kathryn F. Mileham, Edward S. Kim, and William N. William Jr 27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421Erminia Massarelli 28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435Lucia Kim, Geoffrey Liu, and Ming-Sound Tsao 29 Immunologic Approaches to Lung Cancer Therapy, 454Jay M. Lee, Steven M. Dubinett, and Sherven Sharma 30 Novel and Emerging Agents in NSCLC, 464Anne S. Tsao and Jack A. Roth 31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479Vassiliki A. Papadimitrakopoulou 32 Novel Statistical Models for NSCLC Clinical Trials, 488J. Jack Lee and Caleb T. Chu 33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505John V. Heymach and Tina Cascone 34 Anti-angiogenic Agents in Metastatic NSCLC, 527Millie Das and Heather Wakelee 35 Targeting ALK Rearrangements, 541Justin F. Gainor and Alice T. Shaw 36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557Renata Ferrarotto and George R. Simon 37 Prognostic and Predictive Biomarker Signatures, 564Johannes R. Kratz and David M. Jablons 38 Brain Metastasis from Lung Cancer, 572Ritsuko U. Komaki and Amol J. Ghia Index, 591 Color plate section between pages 146 and 147

Read more less

Book SynopsisRare gynecological cancers kill all too commonly Gynecological cancer is a frightening prospect for women. It is terrifying also for physicians who need, but often can t find, guidance on how to investigate and appropriately treat the tumors.Table of ContentsList of Contributors vi Preface viii Part 1 General Principles 1 1 Molecular Targets in Gynecologic Cancers 3 Whitfield Growdon, Rosemary Foster, and Bo Rueda 2 Imaging of Rare Gynecologic Tumors 18 Hima B. Prabhakar and Dinushi S. Perera 3 Pathology Overview of Rare Gynecologic Tumors 35 Robert H. Young Part 2 Rare Ovarian Cancers 51 4 Ovarian Clear Cell Carcinoma 53 Rachel M. Clark and John O. Schorge 5 Mucinous Epithelial Ovarian Cancer 64 Marcela G. del Carmen 6 Pseudomyxoma Peritonei 70 Leslie S. Bradford and Annekathryn Goodman 7 Squamous Cell Carcinoma of the Ovary 81 Ryan J. Spencer and Laurel W. Rice 8 Endometriosis-Associated Ovarian Cancer 94 Leslie A. Garrett and Marcela G. del Carmen 9 Carcinosarcoma of the Ovary 109 J. Alejandro Rauh-Hain and Marcela G. del Carmen 10 Malignant Germ Cell Tumors of the Ovary 120 Marcela G. del Carmen 11 Malignant Sex Cord-Stromal Tumors of the Ovary 132 Marcela G. del Carmen and Richard T. Penson 12 Small Cell and Neuroendocrine Cancers of the Ovary 139 Ariel A. Kaphan and Cesar M. Castro 13 Carcinoid Tumors of the Ovary 148 Michael J. Worley Jr., and Michael G. Muto Part 3 Rare Uterine Cancers 157 14 Uterine Carcinosarcoma 159 Premal H. Thaker and Don S. Dizon 15 Uterine Leiomyosarcoma 167 Marcela G. del Carmen 16 Mucinous Tumors of the Uterine Corpus 178 Rachel M. Clark and Marcela G. del Carmen 17 Uterine Clear Cell Carcinoma 186 J. Alejandro Rauh-Hain, Alexander B. Olawaiye, and David M. Boruta 18 Updates on the Management of Uterine Serous Carcinoma 195 Amanda Ramos and Amanda Nickles Fader 19 Endometrial Stromal Sarcomas 205 Kathleen M. Schmeler, J. Alejandro Rauh-Hain, and Marcela G. del Carmen Part 4 Rare Cancers of the Cervix, Vulva and Vagina 217 20 Small Cell Neuroendocrine Carcinoma of the Cervix 219 Olivia W. Foley, Leslie S. Bradford, and Marcela G. del Carmen 21 Primary Malignant Melanoma of the Vagina and Vulva 228 Alexander B. Olawaiye 22 Sarcomas of the Vulva and Vagina 236 Rachel M. Clark, J. Alejandro Rauh-Hain, and Marcela G. del Carmen 23 Gestational Trophoblastic Disease 245 Whitfield Growdon Index 260

Read more less

Book SynopsisThe first three editions of this acclaimed book presented a much-needed conceptual synthesis of this rapidly moving field. Now, Cancer Cytogenetics, Fourth Edition, offers a comprehensive, expanded, and up-to-date review of recent dramatic advances in this area, incorporating a vast amount of new data from the latest basic and clinical investigations. New contributors reflecting broader international authorship and even greater expertise Greater emphasis throughout on the clinical importance and application of information about cytogenetic and molecular aberrations Includes a complete coverage of chromosome aberrations in cancer based on an assessment of the 60,000 neoplasms cytogenetically investigated to date Now produced in full color for enhanced clarity Covers how molecular genetic data (PCR-based and sequencing information) are collated with the cytogenetic data where pertinent Discusses how molecular cytogeTable of ContentsContributors vii Preface to the Fourth Edition ix 1 How it all began: cancer cytogenetics before sequencing 1Felix Mitelman and Sverre Heim 2 Cytogenetic methods 11David Gisselsson 3 Cytogenetic nomenclature 19Sverre Heim and Felix Mitelman 4 Nonrandom chromosome abnormalities in cancer: an overview 26Sverre Heim and Felix Mitelman 5 From chromosomes to genes: searching for pathogenetic fusions in cancer 42Ioannis Panagopoulos 6 Acute myeloid leukemia 62Bertil Johansson and Christine J. Harrison 7 Myelodysplastic syndromes 126Harold J. Olney and Michelle M. Le Beau 8 Chronic myeloid leukemia 153Thoas Fioretos 9 Chronic myeloproliferative neoplasms 175Peter Vandenberghe and Lucienne Michaux 10 Acute lymphoblastic leukemia 198Christine J. Harrison and Bertil Johansson 11 Mature B] and T]cell neoplasms and Hodgkin lymphoma 252Reiner Siebert and Sietse M. Aukema 12 Tumors of the upper aerodigestive tract 332Susanne M. Gollin 13 Tumors of the lung 361Penny Nymark, Eeva Kettunen and Sakari Knuutila 14 Tumors of the digestive tract 373Georgia Bardi and Sverre Heim 15 Tumors of the urinary tract 401Paola Dal Cin 16 Tumors of the breast 426Manuel R. Teixeira, Nikos Pandis and Sverre Heim 17 Tumors of the female genital organs 447Francesca Micci and Sverre Heim 18 Tumors of the male genital organs 481Manuel R. Teixeira and Sverre Heim 19 Tumors of endocrine glands 497Jörn Bullerdiek and David Gisselsson 20 Tumors of the nervous system 515Petter Brandal and Sverre Heim 21 Tumors of the eye 538Karen Sisley 22 Tumors of the skin 555Fredrik Mertens, Felix Mitelman and Sverre Heim 23 Tumors of bone 566Fredrik Mertens and Nils Mandahl 24 Soft tissue tumors 583Nils Mandahl and Fredrik Mertens Index 615

Read more less

Book SynopsisCancer is one of the most exciting specialties in medicine. This book aspires to convey the authors enthusiasm for oncology and this new edition of Oncology Lecture Notes is a must for students and trainees. There has been a revolution in the practice of oncology.Trade Review"This book...provides a concise but quite complete overview of what oncology is about.The volume is designed for undergraduate students in medicine, but it can be a useful reading also for early trainees and for students in other life science related fields with an interest in cancer research. More experienced physicians and investigators might find the book useful for teaching purposes...Each chapter is very rich of illustrations, schemes, and tables and is ended with a list of key points. Considering also its low price, the book is recommended. (Hematological Oncology 17th June 2017)Table of ContentsPreface vi About the companion website vii Part 1 Introduction to oncology 1 What is cancer? 3 2 The scientific basis of cancer 22 3 The principles of cancer treatment 52 4 Cancer and people 96 Part 2 Types of cancer 5 Breast cancer 107 6 Central nervous system cancers 116 7 Oesophageal cancer 124 8 Gastric cancer 128 9 Hepatobiliary cancer 132 10 Pancreatic cancer 137 11 Colorectal cancer 143 12 Kidney cancer 151 13 Bladder cancer 156 14 Prostate cancer 161 15 Testis cancer 169 16 Gestational trophoblastic disease 175 17 Cervical cancer 178 18 Endometrial cancer 183 19 Ovarian cancer 186 20 Head and neck cancers 193 21 Thyroid cancer 200 22 Adrenal cancers 203 23 Carcinoid tumours 206 24 Pituitary tumours 210 25 Parathyroid cancers 212 26 Lung cancer 214 27 Mesothelioma 224 28 The leukaemias 227 29 Hodgkin’s lymphoma 238 30 Non-Hodgkin’s lymphoma 244 31 Myeloma 252 32 Non-melanoma skin tumours 258 33 Melanoma 264 34 Paediatric solid tumours 271 35 Cancers in teenagers and young adults 279 36 Bone and soft tissue sarcomas 281 37 Cancer of unknown primary 289 38 Immunodeficiency-related cancers 295 Part 3 The practice of oncology 39 Paraneoplastic complications of cancer 303 40 Oncological emergencies 314 41 End of life care 334 42 Cancer survivorship 339 Index 341

Read more less

Book SynopsisManaging urologic cancer by preserving, as opposed to removing, affected tissue, is rapidly becoming the favoured choice for urologists and oncologists. Discover all available options and how to achieve the best possible patient management with this expert guide to the area. The editor, Mark Schoenberg, is an internationally-renown expert in this exciting new area and has recruited an outstanding team featuring some of the leading urologists/oncologists in North America and Europe to assist him.Table of ContentsList of Contributors xiii Preface xvii Cancer Genetics, Cancer Biology, and Tumor Growth and Metastasis: The Interaction of Cancer and Its Host Environment 1Mark C. Markowski and Kenneth J. Pienta Renal Cell Carcinoma 1 Bladder Cancer 3 Prostate Cancer 6 References 12 Pathological Basis of Tumor Characterization: Cytopathology, Surgical Pathology, and How Histo]Morphology Informs Treatment Decision Making 19Oleksandr N. Kryvenko and Fadi Brimo The Kidney 23 The Urothelium 27 The Testis 29 References 30 The Immunobiology of Tumor Ablation 33Rafi Kabarriti and Chandan Guha Manipulating the Immune System to Fight Cancer 33 Can We Take Advantage of Ablative Therapies to Activate the Immune System? 34 Immunomodulatory Properties of HIFU 35 Immunomodulatory Properties of Cryotherapy 36 Immunomodulatory Properties of Radiation Therapy 37 References 38 Computed Tomography of Urologic Malignancies: The Role of MDCT in Renal Cell Carcinoma and Transitional Cell Carcinoma 41Siva P. Raman and Elliot K. Fishman Introduction 41 MDCT Protocol Design 41 Three]Dimensional Reconstructions 44 Neoplasms of the Intrarenal Collecting Systems, Ureters, and Bladder 45 Solid Renal Parenchymal Lesions 49 Conclusion 55 References 55 MRI and Metabolic Imaging 59Louise Dickinson, Francesco Fraioli, Athar Haroon, and Clare Allen Magnetic Resonance Imaging 59 MRI Sequences 59 Clinical Applications of MRI for Prostate Cancer 61 Clinical Applications of MRI for Renal Cancer 63 Clinical Applications of MRI for Bladder Cancer 64 New Advances in MRI 65 Metabolic Imaging 66 Clinical Applications of PET–CT for Prostate Cancer 69 Active Surveillance for Low]Risk Prostate Cancer 113Laurence Klotz Introduction and Background 113 Rationale 113 Genetic Features of Low]Grade Prostate Cancer 114 Metastatic Potential 115 Limitations of PSA Kinetics 116 Role of MRI 116 Implications for Patient Management 117 Eligibility for Surveillance 118 Outcome of Surveillance 119 Modeling 119 AS in Practice 121 Conclusions 121 References 122 Tissue]Preserving Surgical Approaches in Urologic Oncology: The Therapeutic Mechanism for Tumor Ablation 127Ganesh Kartha and J. Stephen Jones Introduction 127 Cryoablation: Extreme Cold for Tumor Necrosis 128 Conclusion 130 References 130 Focal Therapy for Prostate Cancer: An Evidence]Based Approach to Tissue]Preserving Strategies 133Kara L. Watts, Yaalini Shanmugabavan, Victoria Chernyak, and Hashim Uddin Ahmed Introduction 133 Key Concepts in FT for PCa 134 Tissue]Preserving FTs 135 Cryotherapy 135 HIFU 137 Salvage Focal/Hemiablation HIFU 140 IRE 141 Radiation 142 Additional Therapies 143 Implications for Research 144 Conclusions 144 References 145 The Modern Basis for Nephron]Sparing Surgery in Patients with Renal Cancer: Biologic Heterogeneity, the Significance of Tumor Biopsy, and the Changing Roles of Partial Nephrectomy and Tumor Ablation 151Jeffrey J. Tomaszewski, Robert G. Uzzo, and David Y.T. Chen Introduction 151 Principal Treatment Options for SRMs and the Basis for Nephron Preservation 152 Comparative Effectiveness of Radical versus NSS 153 Rationale for Ablative Therapies 154 Treatment Trends for Stage I RCC 157 The Role of RMB 158 Challenges Posed by Intratumoral Heterogeneity 161 Conclusions 161 References 162 Bladder]Preserving Strategies in the Treatment of Urothelial Cancer: The Disease Spectrum and the Dawn of Molecular Surgical Guidance 169Stephan Kruck and Arnulf Stenzl Augmented Cystoscopy 170 Fiber]Optic Probe Technology 171 Conclusion 172 References 172 Image]Guided Thermal Ablation of Adrenal Malignancies 175Kyungmouk Steve Lee, Bradley B. Pua, and Stephen B. Solomon Introduction 175 Clinical Results 175 Preprocedural Evaluation 176 Technical Considerations 178 RFA 178 Microwave Ablation 179 Cryoablation 180 Complications 180 Follow]up 181 Conclusion 182 References 182 Managing Penile Cancer: Integrating Tissue Preservation, Energy]Based Therapeutics, and Surgical Reconstruction 185Arthur L. Burnett Introduction 185 Description 186 Diagnosis and Staging 186 Treatment 189 References 193 Testis Cancer: Testis]Sparing Cancer Surgery 199Nilay M. Gandhi and Pravin K. Rao Introduction 199 Imaging of Testicular Tumors 199 Bilateral Tumors 201 The Advent of Testis]Sparing Surgery 201 Concerns about TSS 201 Indications for TSS 204 Preoperative Considerations and Surgical Technique 204 Postoperative Care and Follow]Up 207 Considerations Regarding Surgical Technique 207 Outcomes of TSS 208 Summary 209 References 210 Nanotechnology: An Evolution in Tissue Preservation and Focal]Targeted Oncologic Therapy 213Kara L. Watts and Joshua M. Stern Introduction 213 Introduction to Nanotechnology 214 Types of Nanoparticles 214 Delivery and Use of Nanoparticles 217 Nanotechnology in Prostate Cancer 219 Imaging in Prostate Cancer 219 Therapeutics in Prostate Cancer 221 Nanotechnology in Renal Cancer 223 Nanotechnology in Other Urologic Cancers 224 Limitations of Nanoparticles 224 Future Directions and Conclusions 225 References 226 Trial Design Issues in the Study of Focal Therapy in Prostate and Kidney Cancer 233John B. Eifler and David F. Penson Issues around Endpoints in Studies of Focal Therapy 234 Issues around Defining the Study Population and the Control Arms of Comparative Studies in Focal Therapy 237 Issues around Selecting the Optimal Study Design in Focal Therapy 238 Conclusion 238 References 239 Index 000

Read more less

Book SynopsisWritten by leading research scientists, this book integrates current knowledge of toxicology and human health through coverage of environmental toxicants, genetic / epigenetic mechanisms, and carcinogenicity. Provides information on lifestyle choices that can reduce cancer risk Offers a systematic approach to identify mutagenic, developmental and reproductive toxicants Helps readers develop new animal models and tests to assess toxic impacts of mutation and cancer on human health Explains specific cellular and molecular targets of known toxicants operating through genetic and epigenetic mechanisms Table of ContentsList of Contributors xix Part One Introduction: The Case for Concern about Mutation and Cancer Susceptibility during Critical Windows of Development and the Opportunity to Translate Toxicology into a Therapeutic Discipline 1 1 What Stressors Cause Cancer and When? 3Claude L. Hughes and Michael D. Waters 1.1 Introduction 3 1.1.1 General Information about Cancer 5 1.1.2 Stressors and Adaptive Responses 8 1.2 What Stressors Cause Cancer and When? 8 1.2.1 Mutagenic MOAs 13 1.2.1.1 DNA Repair 14 1.2.2 Epigenetic MOAs 16 1.2.3 Nongenotoxic Carcinogens, ROS, Obesity, Metabolic, Diet, Environment, Immune, Endocrine MOAs 20 1.2.4 Tumor Microenvironment MOAs 25 1.3 Relevance of Circulating Cancer Markers 26 1.4 Potential Cancer Translational Toxicology Therapies 29 1.4.1 Well-Established/Repurposed Pharmaceuticals 31 1.4.2 GRAS/GRASE, Diet, and Nutraceuticals 34 1.4.2.1 Suppression of Cell Proliferation and Induction of Cell Death 35 1.4.2.2 Anti-Inflammatory Effects: Insights from Various Diseases 36 1.4.2.3 Upregulation of Tumor Suppressor MicroRNAs 38 1.4.2.4 Regulation of Oxidative Stress 38 1.4.2.5 Activation of Signal Transduction Pathways 39 1.4.2.6 Mitigating Inherited Deleterious Mutations 40 1.4.2.7 Mitigating Adverse Epigenetic States 42 1.4.2.8 Paradigm for Study of Cancer Chemoprevention 43 1.5 Modeling and the Future 47 References 51 2 What Mutagenic Events Contribute to Human Cancer and Genetic Disease? 61Michael D. Waters 2.1 Introduction 61 2.1.1 Childhood Cancer, Developmental Defects, and Adverse Reproductive Outcomes 62 2.1.2 Newborn Screening for Genetic Disease 62 2.1.3 Diagnosis of Genetic Disease 63 2.1.4 Familial and Sporadic Cancer 65 2.2 Genetic Damage from Environmental Agents 67 2.3 Testing for Mutagenicity and Carcinogenicity 71 2.4 Predictive Toxicogenomics for Carcinogenicity 73 2.5 Germ Line Mutagenicity and Screening Tests 76 2.6 Reproductive Toxicology Assays in the Assessment of Heritable Effects 80 2.6.1 Segmented Reproductive Toxicity Study Designs 80 2.6.2 Continuous Cycle Designs 81 2.6.2.1 One-Generation Toxicity Study 81 2.6.2.2 Repeat Dose Toxicity Studies 82 2.7 Assays in Need of Further Development or Validation 82 2.7.1 Transgenic Rodent Gene Mutation Reporter Assay 82 2.7.2 Expanded Simple Tandem Repeat Assay 84 2.7.3 Spermatid Micronucleus (MN) Assay 85 2.7.4 Sperm Comet Assay 86 2.7.5 Standardization of Sperm Chromatin Quality Assays 86 2.8 New Technologies 87 2.8.1 Copy Number Variants and Human Genetic Disease 87 2.8.2 Next-Generation Whole Genome Sequencing 88 2.8.3 High-Throughput Analysis of Egg Aneuploidy in C. elegans, and Other Alternative Assay Systems 90 2.9 Endpoints Most Relevant to Human Genetic Risk 91 2.10 Worldwide Regulatory Requirements for Germ Cell Testing 94 2.11 Conclusion 95 Acknowledgments 96 References 96 3 Developmental Origins of Cancer 111Suryanarayana V. Vulimiri and John M. Rogers 3.1 Introduction 111 3.2 Current Trends in Childhood Cancer 112 3.3 Potential Mechanisms of Prenatal Cancer Induction 113 3.4 Ontogeny of Xenobiotic Metabolizing Enzymes and DNA Repair Systems 113 3.5 The Developmental Origins of Health and Disease (DOHaD) Theory 115 3.6 Epigenetic Regulation during Development 115 3.6.1 Critical Periods for Epigenetic Regulation 116 3.7 Mechanisms of Cancer in Offspring from Paternal Exposures 117 3.8 Parental Exposures Associated with Cancer in Offspring 118 3.8.1 Radiation 118 3.8.2 Diethylstilbestrol 119 3.8.3 Tobacco Smoke 120 3.8.4 Pesticides 122 3.8.5 Arsenic 123 3.9 Models for the Developmental Origins of Selected Cancers 124 3.9.1 Breast Cancer 124 3.9.2 Leukemia 127 3.10 Public Health Agencies’ Views on Prenatal Exposures and Cancer Risk 129 3.10.1 The United States Environmental Protection Agency (US EPA) 129 3.10.2 The California Environmental Protection Agency (CalEPA) 131 3.10.3 Washington State Department of Ecology (WA DoE) 133 3.11 Conclusions 134 Acknowledgment 135 References 135 4 The Mechanistic Basis of Cancer Prevention 147Bernard W. Stewart 4.1 Introduction 147 4.2 A Mechanistic Approach 147 4.2.1 Specifying Carcinogens 148 4.2.2 Cancer Risk Factors Without Carcinogen Specification 148 4.3 Preventing Cancer Attributable to Known Carcinogens 149 4.3.1 Involuntary Exposure 149 4.3.1.1 Infectious Agents 149 4.3.1.2 Occupation 150 4.3.1.3 Drugs 151 4.3.1.4 Pollution 152 4.3.1.5 Dietary Carcinogens 152 4.3.2 Tobacco Smoking 153 4.3.2.1 Measures to Limit Availability and Promotion 154 4.3.2.2 Product Labeling, Health Warnings, and Usage Restrictions 154 4.3.2.3 Smoking Cessation 155 4.3.3 Alcohol Drinking 155 4.3.4 Solar and Ultraviolet Radiation 156 4.4 Prevention Involving Complex Risk Factors 157 4.4.1 Workplace Exposures 157 4.4.2 Diet and Overweight/Obesity 157 4.5 Prevention Independent of Causative Agents or Risk Factors 158 4.5.1 Screening 158 4.5.2 Chemoprevention 159 4.6 Conclusion 160 References 160 Part Two Exposures that Could Alter the Risk of Cancer Occurrence, and Impact Its Indolent or Aggressive Behavior and Progression Over Time 171 5 Diet Factors in Cancer Risk 173Lynnette R. Ferguson 5.1 Introduction 173 5.2 Obesity 174 5.3 Macronutrients 175 5.3.1 Protein 176 5.3.2 Lipids 177 5.3.3 Carbohydrates 178 5.4 Micronutrients 181 5.4.1 Vitamins 181 5.4.2 Minerals 184 5.5 Phytochemicals 184 5.5.1 Phytoestrogens 185 5.5.2 Other Phytochemicals 186 5.6 Conclusions 188 References 188 6 Voluntary Exposures: Natural Herbals, Supplements, and Substances of Abuse – What Evidence Distinguishes Therapeutic from Adverse Responses? 199Eli P. Crapper, Kylie Wasser, Katelyn J. Foster, and Warren G. Foster 6.1 Introduction 199 6.1.1 Alcohol 200 6.1.2 Cigarette Smoking 201 6.1.3 Herbals and Supplements 202 6.1.3.1 Melatonin 202 6.1.3.2 Resveratrol 204 6.1.3.3 Dong Quai 205 6.1.3.4 Eleutherococcus 206 6.1.3.5 Saw Palmetto 206 6.1.3.6 Stinging Nettle 207 6.2 Summary and Conclusions 207 References 207 7 Voluntary Exposures: Pharmaceutical Chemicals in Prescription and Over-the-Counter Drugs – Passing the Testing Gauntlet 213Ronald D. Snyder 7.1 Introduction 213 7.2 Testing of New Drug Entities for Genotoxicity 214 7.3 Relationship between Genotoxicity Testing and Rodent Carcinogenicity 217 7.4 Can Drug-Induced Human Cancer Be Predicted? 218 7.5 What Can Rodent Carcinogenicity Tell Us about Human Cancer Risk? 220 7.6 Genotoxicity Prediction Using “Traditional” In Silico Approaches 222 7.7 Covalent versus Noncovalent DNA Interaction 223 7.8 Use of New Technologies to Predict Toxicity and Cancer Risk: High-Throughput Methods 224 7.9 Transcriptomics 225 7.10 Single-Nucleotide Polymorphisms (SNPs) 226 7.11 Conclusions 227 Appendix A 228 References 253 8 Children’s and Adult Involuntary and Occupational Exposures and Cancer 259Annamaria Colacci and Monica Vaccari 8.1 Introduction 259 8.2 Occupational Exposures and Cancer 262 8.2.1 Occupational Cancer in the Twenty-First Century 262 8.2.2 Past and Present Occupational Exposure to Asbestos 263 8.2.3 Toxicology of Fibers: What We Have Learned from the Asbestos Lesson 265 8.2.3.1 Mechanism and Mode of Action of Asbestos and Asbestos-Like Fibers in Carcinogenesis: The Role of Inflammation and Immune System to Sustain the Cancer Process 268 8.2.4 Occupational Exposures and Rare Tumors 270 8.3 Environmental Exposures and Cancer 271 8.3.1 Environmental Exposures and Disease: Is This the Pandemic of the Twenty-First Century? 271 8.3.2 The Complexity of Environmental Exposures 272 8.3.3 Environmental Impact on Early Stages of Life: Are Our Children at Risk? 274 8.3.4 Environmental Endocrine Disruptors: The Steps Set Out to Recover Our Stolen Future 277 8.3.5 From Occupational to Environmental Exposures: Asbestos and Other Chemicals of Concern 279 8.3.5.1 Asbestos 279 8.3.5.2 Arsenic and Arsenic Compounds 280 8.3.5.3 Phthalates 282 8.3.5.4 Pesticides 283 8.3.5.5 Mycotoxins 286 8.3.6 Air Pollution and Airborne Particulate Matter: The Paradigmatic Example of Environmental Mixtures 288 8.3.6.1 Characteristics of PM and PM Exposures 289 8.3.6.2 PM Exposures and Cancer 291 8.3.6.3 Possible Mechanisms of PM Toxicity 293 8.3.6.4 The Role of PM Exposures in the Fetal Origin of the Disease 294 8.4 Conclusions and Future Perspectives 296 References 299 Part Three Gene–Environment Interactions 317 9 Ethnicity, Geographic Location, and Cancer 319Fengyu Zhang 9.1 Introduction 319 9.2 Classification of Cancer 320 9.2.1 Classification by Histology 320 9.2.2 Classification by Primary Location 322 9.3 Ethnicity and Cancer 323 9.3.1 Cancer Death and Incidence 323 9.3.2 Site-Specific Cancer Incidence 326 9.3.3 Site-Specific Cancer Incidence between the United States and China 328 9.4 Geographic Location and Cancer 331 9.4.1 Mapping Human Diseases to Geographic Location 331 9.4.2 Geographic Variation and Cancer in the United States 332 9.5 Ethnicity, Geographic Location, and Lung Cancer 334 9.5.1 Ethnic Differences 334 9.5.2 Geographic Variation 335 9.5.3 Individual Risk Factors 335 9.6 Common Cancers in China 338 9.6.1 Liver Cancer 339 9.6.1.1 Geographic Variation 339 9.6.1.2 Urban Residence and Sex 340 9.6.1.3 Hepatitis B Virus Infection 340 9.6.1.4 Familial Aggregation and Genetic Variants 341 9.6.2 Gastric Cancer 342 9.6.2.1 H. pylori 342 9.6.2.2 Familial Aggregation 343 9.6.2.3 Genetic Susceptibility Factors 343 9.6.3 Esophageal Cancer 344 9.6.3.1 Geographic Variation 344 9.6.3.2 Viral Infections 344 9.6.3.3 Familial Aggregation 345 9.6.3.4 Genetic Susceptibility Factors 345 9.6.4 Lung Cancer 346 9.6.5 Genetic Susceptibility Factors 347 9.6.6 Cervical Cancer 348 9.7 Cancer Risk Factors and Prevention 348 9.7.1 Environmental Chemical Exposure 348 9.7.2 Infectious Agents 349 9.7.3 Psychosocial Stress and Social Network 349 9.7.4 The Developmental Origin of Adult-Onset Cancer 350 9.7.5 Cancer Prevention and Intervention 351 References 353 10 Dietary/Supplemental Interventions and Personal Dietary Preferences for Cancer: Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction 363Sandeep Kaur, Elaine Trujillo, and Harold Seifried 10.1 Introduction 363 10.2 Gene Expression and Epigenetics 364 10.3 Environmental Lifestyle Factors Affecting Cancer Prevention and Risk 366 10.3.1 Obesity 366 10.3.2 Weight Loss 368 10.3.3 Physical Activity 369 10.4 Dietary Patterns 370 10.5 Complementary and Integrative Oncology Interventions/Restorative Therapeutics 373 10.6 Special and Alternative Diets 377 10.7 Popular Anticancer Diets 378 10.7.1 Macrobiotic Diet 378 10.7.2 The Ketogenic Diet 382 10.7.3 Fasting Diet 383 10.8 Conclusion 384 Acknowledgment 384 References 385 11 Social Determinants of Health and the Environmental Exposures: A Promising Partnership 395Lauren Fordyce, David Berrigan, and Shobha Srinivasan 11.1 Introduction 395 11.1.1 Conceptual Model 397 11.1.2 Difference versus Disparity 398 11.2 Social Determinants of Health 399 11.2.1 Race/Ethnicity 399 11.2.2 Social Determinants of Health: “Place” and Its Correlates 402 11.2.3 Gender and Sexuality 405 11.3 Conclusions: Social Determinants of Health and Windows of Susceptibility 407 Acknowledgments 408 References 408 Part Four Categorical and Pleiotropic Nonmutagenic Modes of Action of Toxicants: Causality 415 12 Bisphenol A and Nongenotoxic Drivers of Cancer 417Natalie R. Gassman and Samuel H. Wilson 12.1 Introduction 417 12.2 Dosing 420 12.3 Receptor-mediated Signaling 421 12.4 Epigenetic Reprogramming 422 12.5 Oxidative stress 424 12.6 Inflammation and Immune Response 425 12.7 BPA-Induced Carcinogenesis 426 12.8 Fresh Opportunities in BPA Research 428 References 429 13 Toxicoepigenetics and Effects on Life Course Disease Susceptibility 439Luke Montrose, Jaclyn M. Goodrich, and Dana C. Dolinoy 13.1 Introduction to the Field of Toxicoepigenetics 439 13.1.1 The Epigenome 440 13.1.2 Epigenetic Marks are Heritable and Reversible 440 13.1.3 DNA Methylation 441 13.1.4 Histone Modifications and Chromatin Packaging 442 13.1.5 Noncoding RNAs 443 13.1.6 Key Windows for Exposure-Related Epigenetic Changes 443 13.1.7 Evaluation of Environmentally Induced Epigenetic Changes in Animal Models and Humans 444 13.2 Exposures that Influence the Epigenome 444 13.2.1 Air Pollution 445 13.2.2 Metals 447 13.2.3 Endocrine Disrupting Chemicals (EDCs) 448 13.2.4 Diet 451 13.2.5 Stress 453 13.3 Intergenerational Exposures and Epigenetic Effects 454 13.4 Special Considerations and Future Directions for the Field of Toxicoepigenetics 456 13.4.1 Tissue Specificity 456 13.4.2 The Dynamic Nature of DNA Methylation 458 13.5 Future Directions 459 13.6 Conclusions 460 Acknowledgments 461 References 461 14 Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons 473William H. Bisson, Amedeo Amedei, Lorenzo Memeo, Stefano Forte, and Dean W. Felsher 14.1 Introduction 473 14.2 The Immune System 475 14.2.1 Innate Immune Response 475 14.2.2 Adaptive Immune Response 478 14.3 Prioritized Chemicals 482 14.3.1 Bisphenol A 482 14.3.2 Polybrominated Diphenyl Ethers 483 14.3.3 4-Nonylphenol 485 14.3.4 Atrazine 485 14.3.5 Phthalates 486 14.4 Experimental Models of Carcinogenesis through Inflammation and Immune System Deregulation 487 14.5 Antioxidants and Translational Opportunities 493 14.6 Tumor Control of the Microenvironment 495 Acknowledgments 497 References 497 15 Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology 511R. Brooks Robey 15.1 Introduction 511 15.2 Metabolic Reprogramming and Dysregulation in Cancer 513 15.2.1 Carbohydrate Metabolism in Cancer 515 15.2.2 Lipid Metabolism in Cancer 519 15.2.3 Protein Metabolism in Cancer 521 15.3 Moonlighting Functions 523 15.4 Cancer Metabolism in Context 523 15.4.1 The Gestalt of Intermediary Metabolism 523 15.4.2 Cancer Tissues, Cells, and Organelles as Open Systems 527 15.4.3 The Endosymbiotic Nature of Cancer 527 15.4.4 Catabolic and Anabolic Support of Cell Proliferation 528 15.4.5 Cancer Heterogeneity 529 15.4.6 Phenotypic Relationships between Cancer Cells and Their Parental Cell Origins 532 15.4.7 Evolutionary Perspectives of Metabolic Fitness and Selection in Cancer Development 533 15.5 Dual Roles for Metabolism in Both the Generation and Mitigation of Cellular Stress 536 15.5.1 Metabolism and Oxidative Stress 537 15.5.2 Metabolism and Hypoxic Stress 539 15.5.3 Nutritional Stress and Metabolism 539 15.5.4 Metabolism and Physical Stress 540 15.5.5 Metabolism and Other Forms of Cellular Stress 541 15.6 Models of Carcinogenesis 541 15.6.1 Traditional Multistage Models of Cancer Development 542 15.6.2 Role of Replicative Mutagenesis in Cancer Development 543 15.6.3 Acquired Mismatch Model of Carcinogenesis 543 15.7 Potential Metabolic Targets for Environmental Exposures 546 15.7.1 Conceptual Overview of Potential Metabolic Targets 546 15.7.2 Identification of Key Targetable Contributors to Metabolic Dysregulation and Selection 549 15.7.2.1 Glycolysis 555 15.7.2.2 Lipogenesis, Lipolysis, and the PPP 555 15.7.2.3 Citric Acid Cycle 556 15.7.2.4 Organizational or Compartmental Targets 556 15.7.2.5 Metabolite Transport Mechanisms 557 15.7.2.6 Signal Transduction Effectors 558 15.8 Metabolic Changes Associated with Exposures to Selected Agents 559 15.8.1 Selected Agents Classified by the World Health Organization’s International Agency for Research on Cancer (IARC) 559 15.8.1.1 IARC Group 1 (Carcinogenic to Humans) 560 15.8.1.2 IARC Group 2A (Probably Carcinogenic to Humans) 564 15.8.1.3 IARC Group 2B (Possibly Carcinogenic to Humans) 565 15.8.1.4 Other Agents 565 15.8.2 Environmentally Relevant Combinatorial Exposures 567 15.8.2.1 Occupational and Common Environmental Exposures 567 15.8.2.2 Environmentally Relevant Low-Dose Combinatorial Exposures 568 15.8.2.3 The Halifax Project 570 15.9 A Conceptual Overview of Traditional and Emerging Toxicological Approaches to the Problem of Cancer Metabolism: Implications for Future Research 571 15.9.1 General Experimental Considerations in the Study of Metabolism In Vitro 571 15.9.2 Systems Biology and Current Approaches to In Vitro Toxicology Screening 573 15.10 The Nosology of Cancer and Cancer Development 577 15.11 Discussion 579 Acknowledgments 583 References 583 Part Five Biomarkers for Detecting Premalignant Effects and Responses to Protective Therapies during Critical Windows of Development 607 16 Circulating Molecular and Cellular Biomarkers in Cancer 609Ilaria Chiodi, A. Ivana Scovassi, and Chiara Mondello 16.1 Introduction 609 16.2 Proteins in Body Fluids: Potential Biomarkers 610 16.2.1 Diagnostic Protein Biomarkers 612 16.2.2 Prognostic Protein Biomarkers 613 16.2.3 Protein Biomarkers of Drug Response 615 16.3 Circulating Cell-Free Nucleic Acids 615 16.3.1 Circulating Cell-Free Tumor DNA 616 16.3.1.1 Cf-DNA Integrity, Microsatellite Instability, and LOH 617 16.3.1.2 Tumor-Specific Genetic Alterations 617 16.3.1.3 Tumor Genetic Alterations and Therapy Resistance 619 16.3.1.4 Tumor Epigenetic Alterations: DNA Methylation 620 16.3.2 Circulating Cell-Free RNA 621 16.3.2.1 Circulating Cell-Free microRNA 621 16.4 Extracellular Vesicles: General Features 624 16.4.1 Classification of EVs 624 16.4.2 EVs and Cancer 625 16.4.3 EVs as Mediators of Cell-To-Cell Communication 627 16.5 Circulating Tumor Cells 628 16.5.1 Two-Step Processing of Blood Samples: Enrichment and Identification of Circulating Tumor Cells 628 16.5.1.1 CTC Number as a Cancer Biomarker 630 16.5.2 Characterization of CTCs 630 16.5.2.1 Molecular Characterization of CTCs 630 16.5.2.2 Functional Characterization of CTCs 632 16.5.3 Single CTCs versus CTC Clusters 634 16.5.4 In Hiding Before Getting Home, the Long Journey of CTCs 635 16.6 Conclusions 635 References 637 17 Global Profiling Platforms and Data Integration to Inform Systems Biology and Translational Toxicology 657Barbara A. Wetmore 17.1 Introduction 657 17.2 Global Omics Profiling Platforms 659 17.2.1 Genomics 659 17.2.2 Epigenomics 661 17.2.3 Transcriptomics 662 17.2.4 Proteomics 665 17.2.5 Metabolomics 668 17.3 High-Throughput Bioactivity Profiling 669 17.3.1 High-Throughput Bioactivity and Toxicity Screening 669 17.3.2 In Vitro–In Vivo Extrapolation 671 17.4 Biomarkers 672 17.5 Exposomics 673 17.6 Bioinformatics to Support and Data Integration and Multiomics Efforts 674 17.7 Data Integration: Multiomics and High-Dimensional Biology Efforts 676 17.8 Conclusion 679 References 679 18 Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction 691Rebecca Johnson and David Kerr 18.1 Introduction 691 18.2 The Identification of Novel Predictors of Adverse Events 693 18.2.1 Candidate Gene Studies 693 18.2.2 Genome-wide Associations 694 18.2.3 Next-Generation Sequencing 695 18.3 Proof of Principle Toxgnostics 696 18.4 Proposed Protocol 698 18.4.1 Integration within Randomized Control Trials 698 18.4.2 Biobanking and Future-Proofing Samples 699 18.4.3 Data Protection and Full Consent 702 18.4.4 The Need for a Collaborative Approach 703 18.4.5 Open Access to Results 704 18.4.6 Translation from Bench to Bedside 705 18.5 Fiscal Matters 706 18.6 The Future of Toxgnostics 706 References 707 19 Ethical Considerations in Developing Strategies for Protecting Fetuses, Neonates, Children, and Adolescents from Exposures to Hazardous Environmental Agents 711David B. Resnik and Melissa J. Mills 19.1 Introduction 711 19.2 What Is Ethics? 712 19.2.1 Some Fundamental Ethical Values 712 19.2.1.1 Benefits and Costs 712 19.2.1.2 Individual Rights and Responsibilities 713 19.2.1.3 Justice 713 19.2.2 Value Conflicts and Ethical Decision-Making 713 19.3 Ethical Considerations for Strategies Used to Protect Fetuses, Neonates, Children, and Adolescents from Exposures to Harmful Environmental Agents 715 19.3.1 Education 715 19.3.2 Testing/Screening/Monitoring 717 19.3.3 Worker Protection 720 19.3.4 Government Regulation 722 19.3.5 Taxation 725 19.3.6 Civil Liability 726 19.3.7 Criminal Liability 729 19.4 Research with Human Participants 730 19.4.1 Return of Individualized Research Results 732 19.4.2 Protecting Privacy and Confidentiality 733 19.4.3 Interventional Studies 734 19.4.4 Intentional Exposure Studies 736 19.4.5 Protecting Vulnerable Participants 739 19.5 Conclusion 742 References 742 Index 751

Read more less

Book SynopsisYour trusted, no-nonsense guide to detecting and managing breast cancer From the breast health experts at the American Breast Cancer Foundation comes a sensitive and authoritative guide to the most common cancer in women: breast cancer.Table of ContentsForeword xvii Introduction 1 About This Book 2 Foolish Assumptions 2 Icons Used in This Book 3 Beyond the Book 3 Where to Go from Here 4 Part 1: Knowing About Breast Cancer 5 Chapter 1: Breast Cancer 101 7 Breast Cancer Basics 8 Finding your way around your breast 8 Knowing about breast cancer risk factors and indicators 9 Distinguishing Different Breast Cancers 10 Detecting breast cancer 13 Biopsies and how they work 14 The pathologist and diagnosis 14 Grading and Staging of Breast Cancer 15 Planning Your Treatment 15 Looking at your treatment options 15 Considering breast surgery 16 Treating breast cancer with radiation 17 Treating breast cancer with chemotherapy 17 Treating breast cancer with endocrine (hormonal), biological, and other cutting-edge therapies 17 Treating advanced breast cancer 18 Chapter 2: Risk Factors for Breast Cancer 19 Advanced Age 19 Gender 20 Race and Ethnicity 21 Early Menstruation and Late Menopause 23 Use of Birth Control Pills 23 Genetic Risk: BRCA1 and BRCA2 Genes 23 Poor Nutrition 26 Fats 27 Red meat and processed meats 27 Obesity 28 Smoking 29 Alcohol Use 29 Prior Treatment and Chemical Exposures 30 Exposure to DES (diethylstilbestrol) 30 Hormones: Estrogen and progesterone use 30 Environmental factors 31 Chapter 3: Indicators of Breast Cancer 33 Monitoring Changes in Breast Size and Shape 34 Breast increasing in size 35 Breast decreasing in size 35 Watching for Skin Changes 36 Rash 36 Paget’s disease 36 Skin thickening 37 Cellulitis 37 Mastitis 38 Breast abscess 38 Checking Out Lumps and Bumps 39 Breast masses and fibroadenomas 39 Breast cysts 39 Dense breasts 40 Dealing with Breast Aches and Pains 40 Nipple Changes 41 Nipple inversion 41 Milky nipple discharge 41 Bloody nipple discharge 42 Part 2: Diagnosing Breast Cancer 45 Chapter 4: Physical Awareness and Detecting Breast Cancer 47 What to Look For 49 Doing a Breast Self-Examination 50 In the shower 50 In front of the mirror 50 While lying down 51 Breast Cancer Screening Guidelines 52 Mammograms: The Go-to Tool 55 Tomosynthesis (tomo) mammogram 55 Advantages of screening mammograms 56 Disadvantages of screening mammograms 56 How a mammogram is done 58 Other Screening Tests: MRI and Ultrasound 59 Chapter 5: Understanding Breast Biopsies 63 Knowing What a Breast Biopsy Entails 65 Getting the Right Type of Breast Biopsy 65 Playing an Active Role in Your Breast Biopsy: Before, During, and After 67 Preparing for your biopsy and reducing risks and complications 68 Knowing what to expect on the day of your biopsy 69 Waiting for your biopsy results 70 Making Sense of Your Biopsy Results 71 Grasping some basic medical terminology 71 Sorting out the nuances of “abnormal” 72 Most common types of breast cancer 73 Less common types of breast cancer 73 Digging deeper into the pathology report when cancer is detected 74 Discussing your pathology report 76 Discussing next steps if cancer is found 76 The shades of your pathology result 76 Following up when no cancer is found 77 Chapter 6: Stages of Breast Cancer 79 Testing to Determine Stages 80 Overview of Breast Cancer Staging 80 Early 81 Locally advanced 82 Local recurrence 82 Metastatic or secondary breast cancer 82 Deciphering the TNM Staging System 83 Understanding Breast Cancer Stages 85 Stage 0 (zero) 85 Stage I 85 Stage II 85 Stage III 86 Stage IV 88 Part 3: Treating Breast Cancer 91 Chapter 7: Looking at Treatment Options 93 Surgery 96 Lumpectomy or partial mastectomy (breast- conserving surgery) 96 Mastectomy (total or simple) 96 Modified radical mastectomy 98 Axillary lymph node dissection 98 Breast Reconstruction 101 Radiation Therapy 102 Side effects 103 Skincare during radiation therapy 104 Chemotherapy 105 Endocrine or Hormonal Therapy 106 Targeted Therapy: Herceptin and Others 106 Considering Clinical Trials 109 Randomized controlled trials (RCT) 110 Placebos and double-blind trials 110 Length of clinical trials 111 Chapter 8: Breast Surgery 113 Types of Breast Surgery 114 Preparing for Surgery 115 Talking to your surgeon before surgery 116 Pre-surgical restrictions 117 Special Pre-Surgery Concerns 118 Alcohol consumption 118 Smoking tobacco or cannabis 119 Sleep apnea 119 Following a pre-surgery checklist 121 During the Surgery 122 Post-Surgery Tips 123 Drains and drips 123 Going home 124 Restrictions on activity 124 Chapter 9: Radiation Therapy 127 How Radiation Therapy Works 128 Planning for Radiation Treatment 131 Things to Do before Radiation Therapy 132 Post-Radiation Skincare 133 Radiation Therapy Side Effects 134 Skin reactions 134 Change in breast size and consistency 134 Swelling or edema of the breast 135 Pain in the breast area 135 The Importance of Exercising 135 Warm-up and cool down exercises 135 Basic exercises to do in the first week after surgery or radiation and beyond 136 Advanced exercises for the second week after surgery or radiation and beyond 136 Tiredness and fatigue 137 Lymphedema 137 Change in breast shape, size, and color 137 Hair loss in the armpit or chest area 138 Sore throat 138 Late side effects 138 Chapter 10: Chemotherapy 141 Different Types of Chemotherapy and How They Work 142 How Chemotherapy Is Given 146 Common Side Effects of Different Chemotherapies 147 The “Chemo Brain” Effect 149 Understanding the Oncotype DX Test 150 Who should have an Oncotype Dx test? 151 How does Oncotype DX work? 151 Interpreting the recurrence score 152 Understanding the MammaPrint Test 152 Interpreting MammaPrint results 152 Preparing for Chemotherapy 153 Chemotherapy before surgery: Neoadjuvant chemotherapy 153 Chemotherapy after surgery: Adjuvant chemotherapy 153 Good Questions to Ask Your Doctor 154 Chapter 11: Endocrine, Biological, and Cutting-Edge Therapies 155 Endocrine Therapy in the Treatment of Breast Cancer 156 Side effects of endocrine therapy 157 Preparing for Endocrine Therapy 158 Endocrine therapy before surgery 159 Endocrine therapy after surgery 159 If you can’t have surgery 159 Asking plenty of questions 159 Biological or Targeted Therapy in the Treatment of Breast Cancer 160 Types of biological therapies 161 Trastuzumab and pertuzumab: Monoclonal antibodies 163 Immunotherapy and Cancer Vaccines 164 Cancer vaccines 165 Cancer treatment vaccines 165 The making of a cancer vaccine 165 Cancer vaccine side effects 167 Precision Medicine 168 Benefits of precision medicine 168 Emerging Therapies 168 Targeted therapy: Immunoliposomes 169 Cell signaling 169 Chapter 12: Breast Reconstruction 171 When Should You Have Breast Reconstruction? 172 Immediate breast reconstruction 173 Delayed breast reconstruction 175 Having both breasts removed 176 Methods of Breast Reconstruction 176 Breast implant reconstruction 177 Autologous breast reconstruction 179 Autologous tissue with implant reconstruction 180 Risks of Breast Reconstruction 183 Questions to Ask Your Plastic Surgeon 184 Choosing Among Your Options 185 Chapter 13: Treating Advanced Breast Cancer 187 Treatment Decisions and Treatment Options 188 Treatment decisions for advanced breast cancer 189 Treatment options for advanced breast cancer 189 Endocrine or Hormone Therapy for Advanced Breast Cancer 190 Chemotherapy for Advanced Breast Cancer 191 Biological Therapies for Advanced Breast Cancer 193 Role of HER2 receptors in advanced breast cancer 193 Trastuzumab (Herceptin) 194 Pertuzumab (Perjeta) 195 Denosumab (Prolia, Xgeva) 196 Everolimus (Afinitor) 197 Other issues with biological treatment 199 Radiation Therapy for Advanced Breast Cancer 201 Radiation as injection 201 Side effects of radiation for advanced breast cancer 201 End of Life Concerns 202 Communicating to Providers 203 Part 4: Dealing with Breast Cancer and Everyday Life 205 Chapter 14: Psychosocial Concerns and Breast Cancer Diagnosis 207 Fear and Worry and Their Physical and Emotional Toll 208 Functional Concerns: Work and Home Life 210 Functional capability for occupational activities 211 Fear of infertility 212 Worrying about work and finances 213 Spirituality 214 Seeking Support 215 Purpose and benefits of participating in a support group 215 How support groups are structured and organized 215 How to find a support group 216 Chapter 15: Managing Stress 217 Incorporating Relaxation Techniques 220 Visualization exercise: Lying in a meadow 222 The Importance of Sleep 222 Spirituality and Meditation 224 Tips for finding comfort, meaning, and spiritual support 224 Call for inner peace 225 Health affirmation 226 Chapter 16: Coping with Changes after Treatment 227 Cancer-Related Fatigue 228 Recognizing cancer-related fatigue 228 Managing cancer-related fatigue 229 Dealing with Hair Loss 230 Caring for your hair when it begins to grow back 231 Talking with your healthcare team about hair loss 231 Addressing Skin Changes 232 Understanding discoloration and hyperpigmentation 232 Experiencing Numbness and Tingling: Peripheral Neuropathy 233 Being at increased risk for peripheral neuropathy 234 Knowing the symptoms of peripheral neuropathy 234 Reducing the effects of neuropathy from chemotherapy 235 Relieving constipation induced by neuropathy 236 Checking out medications and treatments prescribed for neuropathy 237 Coping with Lymphedema 238 Knowing the symptoms of lymphedema 239 Treatment for lymphedema 239 Taking preventative measures 240 Resources for lymphedema management 241 Changing Tastes and Smells 242 Countering Changes in Appetite 243 Dealing with weight gain 245 Managing weight gain 246 Dealing with Diarrhea 247 Chapter 17: Cancer Treatment, Fertility, and Sexuality 249 Infertility and Breast Cancer 250 General causes of infertility 250 Fertility and cancer treatment 251 Permanent infertility 253 Temporary infertility 253 Early menopause 254 How to help preserve your fertility 254 Tissue banking and fertility preservation 255 Alternative complementary and alternative medicine fertility treatments 256 Good clinical care practice for infertility 257 The BETTER model approach 257 The emotional side of fertility issues 258 Pregnancy and cancer 258 Sexuality and Breast Cancer 259 Physical effects of cancer treatment on sexuality 259 Sexuality and intimacy 262 Sex after cancer 263 Dating after cancer 265 Chapter 18: Making Healthy Lifestyle Changes 267 Healthy Lifestyle Changes to Lose Weight 268 Healthy Lifestyle Changes for Anxiety and Depression 269 Exercise 269 Quitting Bad Habits Like Smoking, Drinking, and Drug Abuse 272 Quitting smoking 272 Limiting or avoiding alcohol 274 Treatment for alcoholism 275 Overcoming drug abuse 276 Maintaining Good Nutrition and Diet 277 Foods that can increase or lower estrogen 278 Cooking and food preparation 279 Weight Control and Activity 280 Concrete steps to take toward healthier lifestyle changes 281 Quick meals to make for healthy living 282 General Health Guidelines for Optimal Health 283 Part 5: The Part of Tens 285 Chapter 19: Ten Inspiring Breast Cancer Survivors 287 Helen Hosein-Mulloon 288 Linda Doyle 290 Felicia Smith 292 Kelly M 293 Joy Walker 295 Abbie Savadera 296 Rhonda M Smith 297 Rosa Amelia Tena-Krapes 298 Linda Butzner 299 Alice Loh 300 Chapter 20: Ten Ways Family and Friends Can Help You 303 Learn to Listen 303 Be Your Advocate and Note Taker 304 Keep It Lighthearted 304 Distract You with a Surprise 305 Help You Understand That You Need Help 305 Leave a Message after the Tone 305 Ask You Before Bringing Food 306 Buy You Groceries Instead of Bringing Prepared Foods 306 Help Make Life Normal for Your Kids 306 Don’t Forget You 306 Chapter 21: (At Least) Ten Ways Life Can Be Better After Cancer 307 Adopting an Attitude of Gratitude 308 Enjoying the Moment 308 Knowing Why You Deserve Happiness 308 Learning about Your Health 309 Learning to Pick Your Battles 310 Learning to Be in the Here and Now 311 Engaging in Positive Self-Talk and Conversations 311 Managing Physical Changes 312 Achieving Self-Acceptance and the New You 313 Following a Cancer Survivorship Plan 314 Screening for Breast Cancer and Wellness 315 Appendix A: Breast Health Glossary 317 Appendix B: Support Groups, Resources, and Organizations 327 Index 337

Read more less

Book SynopsisCounseling About Cancer A key resource for all genetic counselors and other healthcare providers, this comprehensive reference has been completely updated and reorganized for its fourth edition Over 50 hereditary cancer predisposition genes have now been identified. Genetic testing can be a powerful tool in assessing individual cancer risk and creating robust medical plans, but can also be a complex process, with personal and familial factors carrying real emotional weight. As such, genetic counseling for patients and their families during the process of genetic testing is critical. Counseling about Cancer: Strategies for Genetic Counseling is the only comprehensive resource available for clinicians who want to understand and apply these dimensions of patient care. This updated and reorganized edition provides detailed information designed to be incorporated in a variety of clinical and health-care contexts. Updated with the latest guidance and research, iTable of ContentsForeword xi Preface xiii Acknowledgments xv Chapter 1: Cancer Diagnosis And Treatment 1 1.1. The Diagnosis of Cancer 1 1.2. Tumor Classification 8 1.3. Cancer Treatment 14 1.4. Risk Factors for Cancer 28 1.5. Case Examples 30 1.6. Discussion Questions 33 1.7. Further Reading 33 Chapter 2: Gastrointestinal Cancer Syndromes 35 2.1. Anatomy 36 2.2. Colorectal Cancer 45 2.3. Gastric (Stomach) Cancer 47 2.4. Pancreatic Cancer 49 2.5. Lynch Syndrome 51 2.6. Familial Adenomatous Polyposis/Attenuated Familial Adenomatous Polyposis 62 2.7. MUTYH-Associated Polyposis 68 2.8. NTHL1 Tumor Syndrome 73 2.9. Polymerase Proofreading-Associated Polyposis Syndrome 75 2.10. Juvenile Polyposis Syndrome 79 2.11. Peutz-Jeghers Syndrome 84 2.12. PTEN Hamartoma Tumor Syndromes 88 2.13. Hereditary Mixed Polyposis Syndrome 90 2.14. Serrated Polyposis Syndrome 92 2.15. Hereditary Diffuse Gastric Cancer Syndrome 96 2.16. Familial Atypical Multiple Mole Melanoma Syndrome 101 2.17. Hereditary Pancreatitis/Familial Pancreatitis 105 2.18. Short Reviews 111 2.19. Further Reading 114 Chapter 3: Breast And Gynecological Cancer Syndromes 129 3.1. Anatomy 129 3.2. Overview of Counseling Issues 131 3.3. Selected Breast and Gynecologic Syndromes 133 3.4. Case Examples 157 3.5. Discussion Questions 160 3.6. Further Reading 160 Chapter 4: Rare Tumor Predisposition Syndromes 163 4.1. Overview of Rare Tumor Syndromes 163 4.2. Overview of Counseling Issues with Rare Tumor Syndromes 171 4.3. Clinical Features of Selected Rare Tumor Syndromes 173 4.4. Case Examples 204 4.5. Discussion Questions 207 4.6. Further Reading 207 Chapter 5: Pediatric Tumor Predisposition Syndromes 209 5.1. Counseling Issues 209 5.2. Pediatric Tumor Predisposition Syndromes 213 5.3. Case Examples 262 5.4. Discussion Questions 265 5.5. Further Reading 266 Chapter 6: Cancer Family Histories (Collection And Interpretation) 269 6.1. Collecting a Cancer History 269 6.2. Challenges to Collecting an Accurate History 289 6.3. Interpreting a Cancer History 293 6.4. Case Examples 299 6.5. Discussion Questions 303 6.6. Further Reading 304 Chapter 7: Cancer Risk Assessment And Risk Models 307 7.1. Risk Definitions 308 7.2. Risk Perception and Cancer Risk 310 7.3. Risk Factors 312 7.4. Risk Modeling 318 7.5. Genetics Criteria 330 7.6. Case Examples 333 7.7. Discussion Questions 334 7.8. Further Reading 335 Chapter 8: Genetic Testing Technologies 337 8.1. Older Technologies 338 8.2. Newer Technologies 348 8.3. Clinical Issues 357 8.4. Case Examples 363 8.5. Discussion Questions 365 8.6. Further Reading 366 Chapter 9: Pre-And Post-Test Genetic Counseling 369 9.1. Traditional Pre-Test Genetic Counseling Session 371 9.2. Pre-Test Strategies for Genetic Counselors 384 9.3. Other Pre-Test Genetic Counseling Considerations 387 9.4. Alternative Service Delivery Models for Pre-Test Education 388 9.5. Traditional Post-Test Genetic Counseling 390 9.6. Post-Test Genetic Counseling When the Genetic Counselor Was Not Involved in Pre-Test Education 396 9.7. Possible Patient Reactions to Results 397 9.8. Follow-Up Genetic Counseling 399 9.9. Psychological Assessment Throughout the Genetic Testing Process (see also Chapter 11) 401 9.10. Summary and Future Directions 403 9.11. Case Examples 404 9.12. Discussion Questions 405 9.13. Further Reading 406 Chapter 10: Special Populations And Special Situations 409 10.1. Counseling for Special Populations 409 10.2. Counseling About Unanticipated Results 417 10.3. Case Examples 421 10.4. Discussion Questions 425 10.5. Further Reading 425 Chapter 11: Psychosocial Aspects Of Cancer Genetic Counseling 429 11.1. Contextual Information About Patients 430 11.2. Patient Reactions Coping Responses and Risk Perception 442 11.3. Strategies for Providing Psychosocial Counseling 446 11.4. Strategies for Effective Psychosocial Genetic Counseling 454 11.5. Providing Additional Emotional Support 461 11.6. Case Examples 468 11.7. Discussion Questions 473 11.8. Further Reading 473 Chapter 12: Ethical Issues In Cancer Genetic Counseling And Testing 475 12.1. Bioethical Principles and Framework 476 12.2. Putting Ethics into Practice 484 12.3. Types of Ethical Dilemmas in Cancer Genetic Counseling 492 12.4. Case Examples 501 12.5. Discussion Questions 504 12.6. Further Reading 504 Index 507

Read more less

Book SynopsisAn innovative guide to the practice ofpelvicexenterativesurgery forthemanagementofadvancedpelvicneoplasms Exenterativesurgeryplays animportantrole in themanagement of advanced pelviccancer.However, whilealarge body of evidence regarding outcomes following pelvic exenteration now exists,practical strategies and management options remain unclear.Surgical Management of AdvancedPelvicCanceraddresses thisproblembyassemblingworld-leaders in the fieldto provide insights into the latest techniques and best practices.Itincludesdetailedcoverage of: SurgicalanatomyOperative approaches andexenterativetechniquesReconstruction optionsCurrent evidence on survival and quality of life outcomes Featuring essential informationforthosemanaging patientswithadvancedpelvicneoplasms,Surgical Management of AdvancedPelvicCancerconsolidates thelatest data andpractical advicein one indispensable guide.Table of ContentsList of Contributors viii Preface xiii 1 From Early Pioneers to the PelvEx Collaborative 1 Éanna J. Ryan and P. Ronan O’Connell 2 The Role of the Multidisciplinary Team in the Management of Locally Advanced and Recurrent Rectal Cancer 12 Dennis P. Schaap, Joost Nederend, Harm J.T. Rutten, and Jacobus W.A. Burger 3 Preoperative Assessment of Tumor Anatomy and Surgical Resectability 17 Akash M. Mehta, David Burling, and John T. Jenkins 4 Neoadjuvant Therapy Options for Advanced Rectal Cancer 32 Alexandra Zaborowski, Paul Kelly, and Brian Bird 5 Preoperative Optimization Prior to Exenteration 45 Marta Climent and Miguel Pera 6 Patient Positioning and Surgical Technology 52 Ben Creavin, Michael E. Kelly, and Desmond C. Winter 7 Intraoperative Assessment of Resectability and Operative Strategy 62 Rory Kokelaar, Dean Harris, and Martyn Evans 8 Anterior Pelvic Exenteration 73 Jan W.A. Hagemans, Jan M. van Rees, Joost Rothbarth, Cornelis Verhoef , and Jacobus W.A. Burger 9 Posterior Pelvic Exenteration 85 Werner Hohenberger, Maximilian Brunner, and Susanne Merkel 10 Total Pelvic Exenteration 90 Satish K. Warrier, Andrew C. Lynch, and Alexander G. Heriot 11 Extended Exenterative Resections Involving Bone 97 Timothy Chittleborough, Gordon Beadel, and Frank Frizelle 12 Exenterative Resections Involving Vascular and Pelvic Sidewall Structures 110 Brian K. Bednarski and George J. Chang 13 Extended Exenterative Resections for Recurrent Neoplasm 120 Peter Sagar 14 Pelvic Exenteration in the Setting of Peritoneal Disease 127 Niels Kok, Arend Aalbers, and Geerard Beets 15 Minimally Invasive Pelvic Exenteration 132 Danielle Collins, Christos Kontovounisios, Shahnawaz Rasheed, and Paris Tekkis 16 Stoma Considerations Following Exenteration 138 Gabrielle H. van Ramshorst and Jurriaan B. Tuynman 17 Reconstructive Techniques Following Pelvic Exenteration 149 Dimitrios Patsouras, Alexis Schizas, and Mark George 18 Minimizing Morbidity from Pelvic Exenteration 158 Meara Dean, Alex Colquhoun, Peter Featherstone, Nicola S. Fearnhead, and R. Justin Davies 19 Crisis Management 170 Henrik Kidmose Christensen, Mette Møller Sørensen, and Victor Jilbert Verwaal 20 Quality of Life and Patient-Reported Outcome Measures Following Pelvic Exenteration 177 Daniel Steffens, Cherry Koh, and Michael Solomon 21 Adjuvant Therapy Options after Pelvic Exenteration for Advanced Rectal Cancer 194 Ka On Lam, Jeremy Yip, and Wai Lun Law 22 Adjuvant Therapy Options after Pelvic Exenteration for Gynecological Malignancy 205 Nisha Jagasia 23 Adjuvant Therapy Options for Urological Neoplasms 214 Gregory J. Nason, Clare O’Connell, and Paul K. Hegarty 24 The Role of Re-irradiation for Locally Recurrent Rectal Cancer 223 Johannes H.W. de Wilt and Jacobus W.A. Burger 25 Palliative Pelvic Exenteration 230 Hidde M. Kroon and Tarik Sammour 26 Outcomes of Pelvic Exenteration for Locally Advanced and Recurrent Rectal Cancer 243 Awad M. Jarrar and Scott R. Steele 27 Outcomes Following Exenteration for Urological Neoplasms 255 Frank McDermott, Ian Daniels, Neil Smart, and John McGrath 28 Outcomes Following Exenteration for Gynecological Neoplasms 265 Päivi Kannisto, Fredrik Liedberg, and Marie-Louise Lydrup 29 Mesenchymal and Non-Epithelial Tumors of the Pelvis 283 Eugenia Schwarzkopf and Patrick Boland Index 298

Read more less

Book SynopsisFlow Cytometry of Hematological Malignancies Flow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. Flow Cytometry of Hematological Malignancies has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry's role in diagnosis and analysis. This essential second edition includes: Explorations of more than 70 antigens Full-color illustrations throughout New descriptions of recently discovered markers WHO classifications of hematological neoplastic diseases Helpful tips for result interpretation and analysis Featuring all this andTable of ContentsForeword to the Second Edition xiby Michael J. Borowitz Foreword to the First Edition xiiby Maryalice Stetler-Stevenson Foreword to the First Edition xiiiby Bruno Brando Preface to the Second Edition xv Preface to the First Edition xvi Abbreviations xvii 1 Antigens 1 Clustered (CD) Antigens CD1 3 CD2 5 CD3 8 CD4 17 CD5 21 CD7 24 CD8 26 CD10 30 CD11b 35 CD11c 38 CD13 40 CD14 44 CD15 46 CD16 49 CD19 52 CD20 55 CD22 59 CD23 61 CD24 64 CD25 66 CD26 67 CD27 69 CD28 70 CD30 71 CD33 73 CD34 77 CD38 79 CD43 81 CD45 82 CD45 Isoforms 87 CD49 90 CD56 93 CD57 96 CD61 97 CD62L 98 CD64 99 CD65 101 CD66c 102 CD71 103 CD79 104 CD81 107 CD103 108 CD117 110 CD123 112 CD138 113 CD200 114 CD305 116 CD307 (IRTA) Antigen Family 117 CD371 118 Non clustered (or primarily known with other names) antigens Bcl‐2 Protein 119 Chemokines and Chemokine Receptors 121 CRLF2 128 Cytotoxic Proteins 129 HLA‐DR 130 Immunoglobulins 132 KIR, CD158 isoforms 136 Myeloperoxidase (MPO) 139 NG2 140 PCA‐1 141 ROR1 141 SLAM Molecules and SLAM‐associated Protein (SAP) 142 SOX11 144 T‐cell Receptor (TCR) 145 Terminal Deoxy‐nucleotidyl‐transferase (TdT) 148 Toll‐like Receptors (TLR) 150 VS38 151 ZAP‐70 152 2 Diseases 155 Myeloproliferative neoplasms 157 Chronic myeloid leukemia (CML) 157 Myeloproliferative neoplasms other than CML 160 Chronic neutrophilic leukemia (CNL) 160 Polycythemia vera (PV) 160 Primary myelofibrosis (PMF) 160 Essential thrombocythemia (ET) 160 Chronic eosinophilic leukemia (CEL) 161 Mastocytosis 162 Acute mast‐cell leukemia (AMCL) 162 Chronic mast‐cell leukemia (CMCL) 163 Myelomastocytic leukemia (MML) 163 Myelodysplastic/myeloproliferative neoplasms 164 Chronic myelomonocytic leukemia (CMML) 164 Other myelodysplastic/myeloproliferative neoplasms and related conditions 167 Juvenile myelomonocytic leukemia (JMML) 167 Atypical CML bcr/abl negative (ACML) 167 RAS‐associated autoimmune leukoproliferative disorder (RALD) 167 Myelodysplastic syndromes 168 Myeloid neoplasms with germline predisposition 171 Acute myeloid leukemias 172 AMLs with recurrent genetic anomalies 173 AMLs with chromosomal anomalies 173 AMLs with gene mutations 180 Relationships between genotype and phenotype in cases of AML not recognized as separate entities in WHO 2017 181 AMLs with myelodysplasia‐related changes (AML‐MRC) 182 AMLs not otherwise specified 182 AML with minimal differentiation 182 AML without maturation 183 AML with maturation 183 Acute myelomonocytic leukemia (AMMoL) 183 Acute monoblastic and monocytic leukemia (AMoL) 184 Pure erythroid leukemia (PEL) 185 Acute megakaryoblastic leukemia (AMKL) 186 Acute basophilic leukemia (ABL) 188 Myeloid proliferations associated with Down syndrome 188 Transient abnormal myelopoiesis (TAM) 189 AMLs in patients with Down syndrome 189 Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL) 189 Acute leukemias with ambiguous lineage attribution (ALAL) 192 Acute undifferentiated leukemias (AUL) 192 Mixed phenotype acute leukemias (MPAL) 192 Neoplastic diseases of B and T lymphatic precursors 194 B lymphoblastic leukemia/lymphoma, not otherwise specified (B‐ALL/LBLnos) 195 B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies 197 Relationships between genotype and phenotype in cases of B‐ALL not recognized as separate entities in WHO 2017 201 T lymphoblastic leukemia/lymphoma (T‐ALL/LBL) 202 Early T‐cell precursor lymphoblastic leukemia (ETP‐ALL) 205 NK lymphoblastic leukemia/lymphoma (NK‐ALL/LBL) 205 Neoplastic diseases of mature B cells 206 Chronic lymphocytic leukemia/small lymphocytic lymphoma (B‐CLL/SLL) 206 Familial B‐CLL 215 Richter syndrome 215 Monoclonal B‐cell lymphocytosis (MBL) 216 CLL‐like monoclonal B lymphocytosis 216 Non‐CLL‐like monoclonal B lymphocytosis 216 B‐cell prolymphocytic leukemia (B‐PLL) 216 Lymphoplasmacytic lymphoma (LPL) 218 Heavy chain disease (HCD) 221 γ heavy chain disease 222 μ heavy chain disease 222 α heavy chain disease 222 Hairy cell leukemia (HCL) 222 Hairy cell leukemia, variant (HCL‐v) 226 Hairy cell leukemia, Japanese variant (HCL‐J) 227 Splenic diffuse red pulp lymphoma (SDRPL) 227 Marginal zone lymphomas (MZL) 228 Nodal marginal zone lymphoma (NMZL) 229 Splenic marginal zone lymphoma (SMZL) 230 Extranodal marginal zone lymphoma (EMZL/MALToma) 232 Clonal B‐cell lymphocytosis with MZL‐like phenotype (CBL‐MZ) 233 Follicular lymphoma (FCL) 234 Testicular follicular lymphoma 237 Duodenal type follicular lymphoma 237 Pediatric type follicular lymphoma 237 Primitive cutaneous follicular lymphoma (PCFL) 237 Large B‐cell lymphoma with IRF4 rearrangement 237 Mantle‐cell lymphoma (MCL) 237 Blastic mantle‐cell lymphoma (BMCL) 240 Leukemic non nodal mantle‐cell lymphoma 240 DLBCL not otherwise specified (DLBCLnos) 240 CD5(+) diffuse large cell lymphoma (CD5(+) DLBCL) 243 T‐cell/histiocyte‐rich B‐cell lymphoma (THRLBCL) 243 Primary DLBCL of the CNS (PCNSL) 244 Primary cutaneous DLBCL, “leg type” 244 EBV(+) DLBCLnos 244 DLBCL associated with chronic inflammation (PAL) 245 Fibrin associated DLBCL 245 Lymphomatoid granulomatosis (LYG) 245 Primary mediastinal B‐cell lymphoma (PMBCL) 245 Intravascular large B‐cell lymphoma (IVBCL) 246 ALK‐positive large cell lymphoma (ALK(+) LBCL) 246 Plasmablastic lymphoma (PBL) 247 Primary effusion lymphoma (PEL) 247 HHV8‐associated lymphoproliferative disorders 247 HHV8‐positive DLBCL 248 HHV8‐positive germinotropic lymphoproliferative disorder 248 Burkitt lymphoma (BL) 248 Burkitt leukemia with immature phenotype 250 Burkitt‐like lymphoma with 11q aberrations 251 High‐grade B‐cell lymphoma (HGBL) 251 Plasma cell neoplasms 251 Monoclonal gammopathies of undetermined significance (MGUS) 253 Multiple myeloma (MM) 253 Plasma cell leukemia (PCL) 257 Neoplastic diseases of mature T and NK cells 258 T‐cell prolymphocytic leukemia (T‐PLL) 258 T‐cell large granular lymphocytic leukemia (T‐LGL) 261 Chronic lymphoproliferative disorders of NK cells (CLPD‐NK/CNKL) 263 Aggressive NK‐cell leukemia (ANKL) 266 Adult T‐cell leukemia/lymphoma (ATLL) 266 Extranodal NK/T-cell lymphoma, “nasal type” (ENKTL) 269 Intestinal T‐cell lymphomas (ITCL) 270 Enteropathy‐associated T‐cell lymphoma (EATCL) 270 Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) 272 Indolent gastro‐intestinal T lymphoproliferative disorder (indolent GI T‐LPD) 273 Hepatosplenic T‐cell lymphoma (HSTCL) 273 Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) 275 Mycosis fungoides (MF) 275 Sezary syndrome (SS) 277 Primary cutaneous CD30(+) lymphoproliferative disorders 279 Lymphomatoid papulosis (LyP) 279 Primary cutaneous anaplastic T‐cell lymphoma (pcALCL) 279 Primary cutaneous peripheral T‐cell lymphoma (PTCL) 280 Primary cutaneous TCRγδ(+) T‐cell lymphoma (PCGD‐TCL) 280 Primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T‐cell lymphoma (PCAETL) 280 Primary cutaneous acral CD8(+) T‐cell lymphoma (PCATCL) 280 Primary cutaneous lymphoma of the medium/small CD4(+) T cells (PCSM‐TCL) 281 Peripheral T‐cell lymphoma, not otherwise specified (PTCLnos) 281 Nodal lymphomas of follicular T‐helper derivation 283 Angioimmunoblastic T‐cell lymphoma (AITL) 283 Follicular T‐cell lymphoma (FTCL) 285 Nodal PTCL with follicular T‐helper phenotype 285 Anaplastic large cell lymphoma ALK(+) (ALCL ALK(+)) 285 Anaplastic large cell lymphoma ALK(‐) (ALCL ALK(‐)) 288 Breast implant–associated anaplastic large cell lymphoma (biaALCL) 288 Hodgkin lymphomas 289 Classic Hodgkin lymphoma (CHL) 289 Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) 290 Neoplastic diseases of histiocytic and dendritic cells 291 Histiocytic sarcoma (HS) 292 Langerhans cell histiocytosis (LCH) 292 Indeterminate dendritic cell tumor (IDCT) 292 Interdigitating dendritic cell sarcoma (IDCS) 292 Follicular dendritic cell sarcoma (FDCS) 292 Erdheim–Chester disease (EDC) 292 3 Appendix 293 Acute leukemias not recognized by the 2017 WHO classification 294 Acute leukemia of myeloid/NK precursors (M/NK‐AL) 294 Acute leukemia of myeloid dendritic cells (MDCL) 294 Acute leukemia of Langerhans cells 294 Composite lymphomas 294 Hypereosinophilic syndrome (HES), lymphocyte variant 295 Indolent T lymphoblastic proliferations (iT‐LBP) 295 Polyclonal lymphocytoses of B lymphocytes 298 Persistent polyclonal B‐cell lymphocytosis (PPBL) 298 Persistent polyclonal CD5(+) B‐cell lymphocytosis 298 Persistent polyclonal B‐cell lymphocytosis, Japanese (hairy) variant 298 Polyclonal plasmacytoses 299 Small round (blue) cell tumors (SR(B)CT) 300 References 301 Index 429

Read more less

Book SynopsisTable of ContentsList of contributors xi Preface xxvii Acknowledgments xxix Part 1: INTRODUCTION 1 Cardinal manifestations of cancer 3 James F. Holland, Robert C. Bast, Jr., John C. Byrd, Carlo M. Croce, Ernest Hawk, Fadlo R. Khuri, Raphael E. Pollock, Apostolia M. Tsimberadou, Christopher G. Willett, and Cheryl L.Willman 2 Biological hallmarks of cancer 7 Douglas Hanahan and Robert A.Weinberg Part 2: TUMOR BIOLOGY 3 Molecular biology, genetics, and translational models of human cancer 19 Benno Traub, Florian Scheufele, Srinivas R. Viswanathan, Matthew Meyerson, and David A. Tuveson 4 Oncogenes 49 Marco A. Pierotti, Milo Frattini, Samantha Epistolio, Gabriella Sozzi, and Carlo M. Croce 5 Tumor suppressor genes 73 Fred Bunz and Bert Vogelstein 6 Epigenetic contributions to human cancer 89 Stephen B. Baylin 7 Cancer genomics and evolution 101 William P. D. Hendricks, Aleksandar Sekulic, Alan H. Bryce, Muhammed Murtaza, Pilar Ramos, Jessica D. Lang, Timothy G. Whitsett, Timothy K. McDaniel, Russell C. Rockne, Nicholas Banovich, and Jeffrey M. Trent 8 Chromosomal aberrations in cancer 125 Megan E. McNerney, Ari J. Rosenberg, and Michelle M. Le Beau 9 MicroRNA expression in cancer 143 Serge P. Nana-Sinkam, Mario Acunzo, and Carlo M. Croce 10 Aberrant signaling pathways in cancer 151 Luca Grumolato and Stuart A. Aaronson 11 Differentiation therapy 161 Sai-Juan Chen, Xiao-Jing Yan, Guang-Biao Zhou, and Zhu Chen 12 Cancer stem cells 177 Grace G. Bushnell,Michael D. Brooks, andMax S.Wicha 13 Cancer and cell death 187 John C. Reed 14 Cancer cell immortality: targeting telomerase and telomeres 201 Ilgen Mender, Zeliha G. Dikmen, and JerryW. Shay 15 Cancer metabolism 211 Natalya N. Pavlova, Aparna D. Rao, Ralph J. DeBerardinis, and Craig B.Thompson 16 Tumor angiogenesis 223 John V. Heymach, Amado Zurita-Saavedra, Scott Kopetz, Tina Cascone, MoniqueNilsson, and IreneGuijarro Part 3: QUANTITATIVE ONCOLOGY 17 Cancer bioinformatics 247 John N.Weinstein 18 Systems biology and genomics 261 Saima Hassan, Joe W. Gray, and LauraM.Heiser 19 Statistical innovations in cancer research 269 J. Jack Lee and Donald A. Berry 20 Biomarker based clinical trial design in the era of genomic medicine 285 R.Donald Harvey, Yuan Liu, Taofeek K.Owonikoko, and Suresh S. Ramalingam 21 Clinical and research informatics data strategy for precision oncology 293 Douglas Hartman, Uma Chandran, Michael Davis, Rajiv Dhir,William E. Shirey, Jonathan C. Silverstein, and Michael J. Becich Part 4: CARCINOGENESIS 22 Chemical carcinogenesis 305 Lorne J. Hofseth, AinsleyWeston, and Curtis C. Harris 23 Ionizing radiation 325 David J. Grdina 24 Ultraviolet radiation carcinogenesis 333 James E. Cleaver, Susana Ortiz-Urda, and Sarah Arron 25 Inflammation and cancer 339 Jelena Todoric, Atsushi Umemura, Koji Taniguchi, and Michael Karin 26 RNA tumor viruses 347 Robert C. Gallo and Marvin S. Reitz 27 Herpesviruses 359 Jeffrey I. Cohen 28 Papillomaviruses and cervical neoplasia 367 Michael F. Herfs, Christopher P. Crum, and KarlMunger 29 Hepatitis viruses and hepatoma 373 HongyangWang 30 Parasites 379 Mervat El Azzouni, Charbel F. Matar, Radwa Galal, Elio Jabra, and Ali Shamseddine Part 5: EPIDEMIOLOGY, PREVENTION, AND DETECTION 31 Cancer epidemiology 391 Veronika Fedirko, Kevin T. Nead, Carrie Daniel, and Paul Scheet 32 Hereditary cancer syndromes: risk assessment and genetic counseling 403 Rachel Bluebond, Sarah A. Bannon, Samuel M. Hyde, Ashley H.Woodson, Nancy Y.-Q. You, Karen H. Lu, and Banu Arun 33 Behavioral approaches to cancer prevention 425 Roberto Gonzalez and Maher Karam-Hage 34 Diet and nutrition in the etiology and prevention of cancer 433 Steven K. Clinton, Edward L. Giovannucci, Fred K. Tabung, and Elizabeth M. Grainger 35 Chemoprevention of cancer 453 Ernest Hawk, Karen C. Maresso, Powel Brown, Michelle I. Savage, and Scott M. Lippman 36 Cancer screening and early detection 473 OtisW. Brawley Part 6: CLINICAL DISCIPLINES 37 Clinical cancer genomic diagnostics and modern diagnostic pathology 493 Katherine Roth, Stephen B. Gruber, and Kevin McDonnell 38 Molecular diagnostics in cancer 505 Zachary L. Coyne, Roshni D. Kalachand, Robert C. Bast Jr., Gordon B. Mills, and Bryan T. Hennessy 39 Principles of imaging 519 Lawrence H. Schwartz 40 Interventional radiology for the cancer patient 521 Zeyad A. Metwalli, Judy U. Ahrar, andMichael J. Wallace 41 Principles of surgical oncology 531 ToddW. Bauer, Kenneth K. Tanabe, and Raphael E. Pollock 42 Principles of radiation oncology 543 Scott R. Floyd, Justus Adamson, Philip P. Connell, Ralph R.Weichselbaum, and Christopher G.Willett 43 Principles of medical oncology 553 Apostolia M. Tsimberidou, Robert C. Bast, Jr., Fadlo R. Khuri, and John C. Byrd 44 Pain and palliative care 567 Laura Van Metre Baum and Cardinale B. Smith 45 Psycho-oncology 577 Diya Banerjee and Andrew J. Roth 46 Principles of cancer rehabilitation medicine 585 Michael D. Stubblefield, Miguel Escalon, Sofia A. Barchuk, Krina Vyas, and David C.Thomas 47 Integrative oncology in cancer care 593 Gabriel Lopez,Wenli Liu, Santhosshi Narayanan, and Lorenzo Cohen 48 Health services research 599 Michaela A. Dinan and Devon K. Check Part 7: INDIVIDUALIZED TREATMENT 49 Precision medicine in oncology drug development 613 Apostolia M. Tsimberidou, Elena Fountzilas, and Razelle Kurzrock Part 8: CHEMOTHERAPY 50 Drug development of small molecule cancer therapeutics in an Academic Cancer Center 631 Christopher C. Coss, Jeffrey T. Patrick, Damien Gerald, Gerard Hilinski, Reena Shakya, and John C. Byrd 51 Principles of dose, schedule, and combination therapy 641 Joseph P. Eder and Navid Hafez 52 Pharmacology of small-molecule anticancer agents 655 Zahra Talebi, Sharyn D. Baker, and Alex Sparreboom 53 Folate antagonists 667 Lisa Gennarini, Peter D. Cole, and Joseph R. Bertino 54 Pyrimidine and purine antimetabolites 679 Robert B. Diasio and StevenM. Offer 55 Alkylating agents and platinum antitumor compounds 693 Zahid H. Siddik 56 DNA topoisomerase targeting drugs 701 AnishThomas, Susan Bates,William D. Figg, Sr., and Yves Pommier 57 Microtubule inhibitors 717 Giuseppe Galletti and Paraskevi Giannakakou 58 Drug resistance and its clinical circumvention 731 Jeffrey A. Moscow, Shannon K. Hughes, Kenneth H. Cowan, and Branimir I. Sikic Part 9: BIOLOGICAL AND GENE THERAPY 59 Cytokines, interferons, and hematopoietic growth factors 739 Narendranath Epperla,Walter Hanel, and Moshe Talpaz 60 Monoclonal antibody and targeted toxin therapy 755 Robert C. Bast, Jr. andMichael R. Zalutsky 61 Vaccines and immunomodulators 781 Jeffrey Schlom, Sofia R. Gameiro, Claudia Palena, and James L. Gulley 62 T cell immunotherapy of cancer 789 M. Lia Palomba, Jae H. Park, and Renier Brentjens 63 Cancer immunotherapy 799 Padmanee Sharma, Swetha Anandhan, Bilal A. Siddiqui, Sangeeta Goswami, Sumit K. Subudhi, Jianjun Gao, Karl Peggs, Sergio Quezada, and James P. Allison 64 Cancer gene therapy 817 Haruko Tashiro, Lauren Scherer, and Malcolm Brenner 65 Cancer nanotechnology 825 Xingya Jiang, Yanlan Liu, Danny Liu, Jinjun Shi, and Robert Langer 66 Hematopoietic cell transplantation 833 Qaiser Bashir, Elizabeth J. Shpall, and Richard E. Champlin Part 10: SPECIAL POPULATIONS 67 Principles of pediatric oncology 847 Theodore P. Nicolaides, Elizabeth Raetz, andWilliam L. Carroll 68 Cancer and pregnancy 867 Jennifer K. Litton 69 Cancer and aging 877 Ashley E. Rosko, Carolyn J. Presley, Grant R.Williams, and Rebecca L. Olin 70 Disparities in cancer care 885 OtisW. Brawley 71 Neoplasms in people living with human immunodeficiency virus 895 Chia-Ching J.Wang and Elizabeth Y. Chiao 72 Cancer survivorship 911 Lewis Foxhall Part 11: DISEASE SITES 73 Primary neoplasms of the brain in adults 921 Matthew A. Smith-Cohn and Mark R. Gilbert 74 Neoplasms of the eye and orbit 933 Erica R. Alvarez, Claudia M. Prospero Ponce, Patricia Chevez-Barrios, and Dan S. Gombos 75 Neoplasms of the endocrine glands and pituitary neoplasms 943 Rui Feng, Chirag D. Gandhi, Margaret Pain, and Kalmon D. Post 76 Neoplasms of the thyroid 949 Matthew D. Ringel 77 Malignant tumors of the adrenal gland 961 Jeffrey E. Lee, Mouhammed A. Habra, andMatthew T. Campbell 78 Tumors of the diffuse neuroendocrine and gastroenteropancreatic system 971 Evan Vosburgh 79 Neoplasms of the head and neck 981 Robert L. Ferris, AdamS. Garden, andNabil F. Saba 80 Cancer of the lung 1005 Daniel Morgensztern, Daniel Boffa, Alexander Chen, Andrew Dhanasopon, Sarah B. Goldberg, Roy H. Decker, Siddhartha Devarakonda, Jane P. Ko, Luisa M. Solis Soto, Saiama N.Waqar, Ignacio I.Wistuba, and Roy S. Herbst 81 Malignant pleural mesothelioma 1029 Michele Carbone, Daniel R. Gomez, Anne S. Tsao, Haining Yang, and Harvey I. Pass 82 Thymomas and thymic tumors 1043 Mayur D. Mody,Gabriel L. Sica, Suresh S. Ramalingam, and Dong M. Shin 83 Tumors of the heart and great vessels 1055 Moritz C.Wyler von Ballmoos and Michael J. Reardon 84 Primary germ cell tumors of the thorax 1061 John D. Hainsworth and Frank A. Greco 85 Neoplasms of the esophagus 1065 MaxW. Sung and Virginia R. Litle 86 Carcinoma of the stomach 1083 Carl Schmidt, Nour Daboul, Carly Likar, and JoshuaWeir 87 Primary neoplasms of the liver 1095 Hop S. Tran Cao, Junichi Shindoh, and Jean-Nicolas Vauthey 88 Gallbladder and bile duct cancer 1109 Mariam F. Eskander, Christopher T. Aquina, and Timothy M. Pawlik 89 Neoplasms of the exocrine pancreas 1123 Robert A. Wolff, Donghui Li, AnirbanMaitra, Susan Tsai, Eugene Koay, and Douglas B. Evans 90 Neoplasms of the appendix and peritoneum 1139 Annie Liu, Diana Cardona, and Dan Blazer 91 Carcinoma of the colon and rectum 1147 Yota Suzuki, Douglas S. Tyler, and Uma R. Phatak 92 Neoplasms of the anus 1169 Alexandre A. A. Jácome and Cathy Eng 93 Renal cell carcinoma 1181 Claude M. Grigg, Earle F. Burgess, Stephen B. Riggs, Jason Zhu, and Derek Raghavan 94 Urothelial cancer 1191 Derek Raghavan, Richard Cote, Earle F. Burgess, Derek McHaffie, and Peter E. Clark 95 Neoplasms of the prostate 1201 Ana Aparicio, Patrick Pilie, Devaki S. Surasi, Seungtaek Choi, Brian F. Chapin, Christopher J. Logothetis, and Paul G. Corn 96 Tumors of the penis and the urethra 1239 Jad Chahoud, Andrea Necchi, and Philippe E. Spiess 97 Testis cancer 1245 Michael Hawking, Gladell Paner, Scott Eggener, and Walter M. Stadler 98 Neoplasms of the vulva and vagina 1261 Michael Frumovitz and Summer B. Dewdney 99 Neoplasms of the cervix 1275 Anuja Jhingran 100 Endometrial cancer 1299 Shannon N.Westin, Karen Lu, and Jamal Rahaman 101 Epithelial ovarian, fallopian tube, and peritoneal cancer 1311 Jonathan S. Berek, Malte Renz, Michael L. Friedlander, and Robert C. Bast, Jr. 102 Nonepithelial ovarian malignancies 1329 Jonathan S. Berek, Malte Renz, Michael L. Friedlander, and Robert C. Bast, Jr. 103 Molar pregnancy and gestational trophoblastic neoplasia 1343 Neil S. Horowitz, Donald P. Goldstein, and Ross S. Berkowitz 104 Gynecologic sarcomas 1351 Jamal Rahaman and Carmel J. Cohen 105 Neoplasms of the breast 1361 Debu Tripathy, Sukh Makhnoon, Banu Arun, Aysegul Sahin, Nicole M. Kettner, Senthil Damodaran, Khandan Keyomarsi,Wei Yang, Kelly K. Hunt, Mark Clemens, Wendy A. Woodward, Melissa P.Mitchell, Rachel Layman, Evthokia A. Hobbs, Bora Lim, MeganDupuis, Rashmi Murthy, Omar Alhalabi, Nuhad Ibrahim, Ishwaria M. Subbiah, and Carlos Barcenas 106 Malignant melanoma 1413 Michael J. Carr, JustinM. Ko, SusanM. Swetter, Scott E. Woodman, Vernon K. Sondak, Kim A. Margolin, and Jonathan S. Zager 107 Other skin cancers 1437 Stacy L. McMurray,William G. Stebbins, Eric A. Millican, and Victor A. Neel 108 Bone tumors 1451 Timothy A. Damron 109 Soft tissue sarcomas 1477 Katherine A.Thornton, Elizabeth H. Baldini, Robert G. Maki, Brian O’Sullivan, Yan Leyfman, and Chandrajit P. Raut 110 Myelodysplastic syndromes 1501 Uma M. Borate 111 Acute myeloid leukemia in adults: mast cell leukemia and other mast cell neoplasms 1517 RichardM. Stone, Charles A. Schiffer, and Daniel J. DeAngelo 112 Chronic myeloid leukemia 1537 Jorge Cortes, Richard T. Silver, and Hagop Kantarjian 113 Acute lymphoblastic leukemia 1547 Elias Jabbour, Nitin Jain, Hagop Kantarjian, and Susan O’Brien 114 Chronic lymphocytic leukemia 1559 Jacqueline C. Barrientos, Kanti R. Rai, and Joanna M. Rhodes 115 Hodgkin lymphoma 1569 David J. Straus and Anita Kumar 116 Clonal hematopoiesis in cancer 1579 Philipp J. Rauch and David P. Steensma 117 Non-Hodgkin’s lymphoma 1587 Arnold S. Freedman and Ann S. LaCasce 118 Mycosis fungoides and Sézary syndrome 1603 Walter Hanel, Catherine Chung, and John C. Reneau 119 Plasma cell disorders 1611 Andrew J. Yee, Teru Hideshima, Noopur Raje, and Kenneth C. Anderson 120 Myeloproliferative disorders 1633 Jeanne Palmer and Ruben Mesa Part 12: MANAGEMENT OF CANCER COMPLICATIONS 121 Neoplasms of unknown primary site 1647 John D. Hainsworth and Frank A. Greco 122 Cancer cachexia 1659 Assaad A. Eid, Rachel Njeim, Fadlo R. Khuri, and David K.Thomas 123 Antiemetic therapy 1673 Michael J. Berger andDavid S. Ettinger 124 Neurologic complications of cancer 1683 Luis Nicolas Gonzalez Castro, Tracy T. Batchelor, and Lisa M. DeAngelis 125 Dermatologic complications of cancer chemotherapy 1701 Anisha B. Patel, Padmavathi V. Karri, and Madeleine Duvic 126 Skeletal complications 1715 Michael A. Via, Ilya Iofin, Jerry Liu, and Jeffrey I. Mechanick 127 Hematologic complications and blood bank support 1729 Roger Belizaire and Kenneth C. Anderson 128 Coagulation complications of cancer patients 1739 Tzu-FeiWang and Kristin Sanfilippo 129 Urologic complications related to cancer and its treatment 1747 Omar Alhalabi, Ala Abudayyeh, and Nizar M. Tannir 130 Cardiac complications 1757 Michael S. Ewer, Steven M. Ewer, andThomas M. Suter 131 Respiratory complications 1779 Vickie R. Shannon, George A. Eapen, Carlos A. Jimenez, Horiana B. Grosu, Rodolfo C. Morice, Lara Bashoura, Ajay Sheshadre, Scott E. Evans, Roberto Adachi, Michael Kroll, Saadia A. Faiz, Diwakar D. Balachandran, Selvaraj E. Pravinkumar, and Burton F. Dickey 132 Gastrointestinal and hepatic complications in cancer patients 1811 Robert S. Bresalier, Emmanuel S. Coronel, and Hao Chi Zhang 133 Oral complications of cancer and their treatment 1827 Stephen T. Sonis, Anna Yuan, and Alessandro Villa 134 Gonadal complications 1839 RobertW. Lentz and Catherine E. Klein 135 Sexual dysfunction 1849 Leslie R. Schover 136 Endocrine complications and paraneoplastic syndromes 1855 Sai-Ching J. Yeung and Robert F. Gagel 137 Infections in patients with cancer 1869 Harrys A. Torres, Dimitrios P. Kontoyiannis, and Kenneth V.I. Rolston 138 Oncologic emergencies 1883 Sai-Ching J. Yeung and Carmen P. Escalante Part 13: THE FUTURE OF ONCOLOGY 139 A vision for twenty-first century healthcare 1907 Leroy Hood, Nathan D. Price, and James T. Yurkovich Index 1915

Read more less

Book SynopsisTHE APPLICATION OF HEAT IN ONCOLOGY Understand the use of heat to destroy tumors with this comprehensive guide Heat is an indispensable resource in the destruction of cancerous tumors to potentially treat cancers. There are also real challenges, however, involved in the total destruction of tumors without destroying healthy tissue surrounding the tumor in the process. A detailed understanding of the propagation of thermal energy, induced heating, and tissue responses to heat is required to safely and successfully apply heat-based technologies in clinical oncology. The Application of Heat in Oncology supplies this understanding, with a thorough, comprehensive overview of the principle and practice involved. Offering both a detailed introduction to the physics and thermodynamics of induced heat and an analysis of its clinical applications, this is an essential resource for clinicians, technicians, and others in oncological practice. The Application of Heat in Oncology readers will also find: Guidelines for applying heat both safely and effectivelyDetailed discussion of topics including energy delivery (e.g., via RF, MW, ultrasound, laser, cryoagents, hyperthermia, nanoparticles, etc.), temperature assessment, damage assessment, image guidance, and moreSummary of current practice along with suggestions for future areas of technological improvement The Application of Heat in Oncology is ideal for all clinicians working in the field of cancer treatment, including medical students, residents, researchers, engineers, radiologists, surgeons, and more.Table of ContentsList of Contributors xxi Preface xxv Part A Principles 1 A.1 Delivering Energy 3 1 Propagation of Radiofrequency and Microwaves in Tissue 5Punit Prakash and Anna Bottiglieri 2 Propagation of Focused Ultrasound in Tissue 19Gregory T. Clement 3 Propagation of Light in Tissue 31Do-Hyun Kim 4 Mechanisms of Tissue Injury in Cryosurgery 45John G. Baust, Kimberly L. Santucci, Kristi K. Snyder, Anthony Robilotto, and John M. Baust 5 Delivering Energy using Localized Hyperthermia Systems 73Hana Dobsicek Trefna, Johannes Crezee, and Petra Kok 6 Role of Nanoparticles Mediated Heating in Oncology 95Gennaro Bellizzi A.2 Assessing Temperatures 107 7 Temperature Monitoring During Thermal Treatment by Thermocouples and Thermistors: Current Status and Perspectives 109Francesca De Tommasi, Carlo Massaroni, Daniela Lo Presti, Rosario Francesco Grasso, Massimiliano Carassiti, Yuman Fong, and Emiliano Schena 8 Fluorescent-Decay Temperature Probes for Biomedical Applications: Theory, Techniques, and Practical Advice 121Daryl James and Harry Vine 9 Calibration and Use of Infrared Thermal Cameras in Biological Applications 135Michael L. Denton and Gary D. Noojin 10 Magnetic Resonance Thermometry in Oncology: Applications in Moving Organs 149Henrik Odéen and Dennis L. Parker 11 Measuring Tissue Temperature with Ultrasound 175Elyas Shaswary and Jahangir (Jahan) Tavakkoli 12 Current Status and Future Potential of Thermometry Based on Computed Tomography Imaging 195Francesca De Tommasi, Carlo Massaroni, Daniela Lo Presti, Rosario Francesco Grasso, Massimiliano Carassiti, Yuman Fong, and Emiliano Schena 13 A Generic Thermal Model to Predict Temperatures in Perfused Tissues 205Devashish Shrivastava A.3 Assessing Damage 217 14 Measuring Thermal Damage with Gross and Microscopic Pathology 219Sharon Thomsen 15 Assessing Thermal Damage with Magnetic Resonance Imaging 251Sara L. Johnson and Allison H. Payne 16 Ultrasound Imaging Techniques for the Evaluation of Thermal Damage 273Jenna Osborn 17 Mathematical Models of Thermal Damage and Cell Death 289John Pearce 18 A Novel Method to Indicate Onset of Photothermal Damage 307Michael L. Denton, Gary D. Noojin, and Elharith M. Ahmed 19 Thermodynamic Challenges of Using Magnetic Resonance Thermometry in Measuring in vivo Temperatures and Estimating Thermal Damage in Thermal Ablation 329Devashish Shrivastava Part B Clinical Applications 341 20 Biological and Physical Aspects of Heat Therapy 343Abhijit Mandal, Ritusha Mishra, and Himanshu Mishra 21 Guiding Thermal Therapy with MR 359Richard Tyc and Mark G. Torchia 22 Role of Radiofrequency Ablation and Laser-Induced Thermal Therapy in the Management of Functional Neurosurgery and Brain Lesions 377Peter Konrad, Johnie Hodge, and Manish Ranjan 23 Radiofrequency and Microwave Thermal Ablation in Cancer Therapy and the Role of Hydrodissection 391Arvind K. Chaturvedi 24 Role of High-Intensity Focused Ultrasound for Functional Neurosurgery and for the Management of Brain Lesions 403Georgios A. Maragkos, Georgios Mantziaris, Shayan Moosa, and W. Jeffrey Elias 25 Role of HIFU in Cancer Management 425Sofia Gereta, Judith Stangl-Kremser, Tenny R. Zhang, and Jim C. Hu 26 Percutaneous Cryoablation: Mechanism of Action, Clinical Applications, and Outcomes 459Ahmed Farhan, Christopher R. Bailey, and Christos Georgiades 27 Clinical Applications of Hyperthermia 483Himanshu Mishra, Ritusha Mishra, and Abhijit Mandal 28 Thermal Damage due to a Monopole Microwave Antenna 499Marta Cavagnaro and Devashish Shrivastava 29 Thermal Damage with High-Intensity Focused Ultrasound 511Devashish Shrivastava 30 Thermal Damage Due to Laser 519Rahul Goyal and Devashish Shrivastava 31 Thermal Damage Due to Hot and Cold Surfaces 525Devashish Shrivastava 32 MRI-Induced RF Heating Considerations for Devices and Accessories that are Partially in and Partially Out of the Human Body 533Ran Guo, Md Zahidul Islam, Wolfgang Kainz, and Ji Chen References 542 Index 545

Read more less

Book SynopsisTargeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. The work primarily focuses on how to understand and translate fundamental principles of basic science into informatiTable of ContentsList of Contributors xix Volume Foreword xxiv Volume Preface xxvi Series Preface xxviii Section I Biological Basis of the Lymphoid Malignancies 1 1 Fundamental Principles of Lymphomagenesis 3Pierre Sujobert, Philippe Gaulard, and Laurence de Leval 2 Identifying Molecular Drivers of Lymphomagenesis 12Jennifer Shingleton and Sandeep S. Dave 3 Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies 25Sean Harrop, Michael Dickinson, Ricky Johnstone, and Henry Miles Prince 4 Animal Models of Lymphoid Malignancies 40Anjali Mishra Section II Targeting the PI3 Kinase-AKT-mTOR Pathway 53 5 Principles of PI3K Biology and Its Role in Lymphoma 55Ralitsa R. Madsen 6 Pharmacologic Differentiation of Drugs Targeting the PI3K-AKT-mTOR Signaling Pathway 71Inhye E. Ahn, Jennifer R. Brown, and Matthew S. Davids 7 Clinical Experience with Phosphatidylinositol 3-Kinase Inhibitors in Hematologic Malignancies 86Alessandro Broccoli and Pier Luigi Zinzani 9 PI3 Kinase, AKT, and mTOR Inhibitors 113Joel McCay and John G. Gribben Section III Targeting Programmed Cell Death 131 10 Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology 133Sarah T. Diepstraten, John E. La Marca, David C.S. Huang, and Gemma L. Kelly 11 Pharmacologic Features of Drugs Targeting BCL2 Family Members 151Jennifer K. Lue and Owen A. O’Connor 12 Clinical Experience with Pro-Apoptotic Agents 165Thomas E. Lew and John F. Seymour 13 Promising Combinations of Drugs Targeting Apoptosis 186William G. Wierda Section IV Targeting the Cancer Epigenome 197 14 The Role of Epigenetic Dysregulation in Lymphoma Biology 199Qing Deng and Michael R. Green 15 Quantitating and Characterizing the Effects of Epigenetic Targeted Drugs 209Emily Gruber, Alexander C. Lewis, and Lev M. Kats 16 Clinical Experience with Epigenetic Drugs in Lymphoid Malignancies 225Enrica Marchi, Ipsita Pal, and John Sanil Manavalan 17 Future Prospects for Targeting the Epigenome in Lymphomas 236Yusuke Isshiki and Ari Melnick Section V Targeting the B-cell Receptor (BCR) 249 18 The Pathologic Role of BCR Dysregulation in Lymphoid Malignancies 251Jan A. Burger 19 Pharmacologic Features of Drugs Targeting Bruton’s Tyrosine Kinase (BTK) 268Joel McCay and John G. Gribben 20 Clinical Experience with Drugs Targeting Bruton’s Tyrosine Kinase (BTK) 278Julia Aronson, Anthony R. Mato, Catherine C. Coombs, Prioty Islam, Lindsey E. Roeker, and Toby Eyre 21 Promising Combinations of BTK Inhibitors with Other Targeted Agents 287Nicholas J. Schmidt, Michael E. Williams, and Craig A. Portell Section VI Protein Degraders and Membrane Transport Inhibitors 301 22 The Biological Basis for Targeting Protein Turnover in Malignant Cells 303Robert Z. Orlowski 23 Preclinical Overview of Drugs Affecting Protein Turnover in Multiple Myeloma 313Giada Bianchi, Matthew Ho, and Kenneth C. Anderson 24 Clinical Experience on Proteasome Inhibitors in Cancer 331Noa Biran, Pooja Phull, and Andre Goy 25 Targeting Nuclear Protein Transport with XPO Inhibitors in Lymphoma 361Farheen Manji, Kyla Trkulja, Rob C. Laister, and John Kuruvilla 26 Heterobifunctional Degraders for the Treatment of Lymphoid Malignancies 372Ashwin Gollerkeri, Jared Gollob, and Nello Mainolfi Section VII Novel Targets and Therapeutic Prospects in Development 381 27 Strategies for Targeting the JAK-STAT Pathway in Lymphoid Malignancies 383David J. Feith, Johnson Ung, Omar Elghawy, Peibin Yue, James Turkson, and Thomas P. Loughran Jr 28 Strategies for Targeting MYC 402Jemma Longley and Andrew Davies 29 Targeting NOTCH in Lymphoid Malignancies 411Deborah Piffaretti, Georgia Alice Galimberti, and Davide Rossi 30 Targeting NF-κB in Oncology, an Untapped Therapeutic Potential 428Matko Kalac 31 Targeting the Cell Cycle and Cyclin-dependent Kinases 444Chiara Tarantelli and Francesco Bertoni References 452 Index 457

Read more less

Book SynopsisTable of ContentsEditors Volume 2 xii Preface xiii Author Bios xv Acknowledgement xvii Volume 1: Solid Tumors & Supportive Care Volume 1 Editors:Syed A. Abutalib, Maurie Markman, Al B. Benson III, and Hope S. Rugo Part 1 Acute Lymphoblastic Leukemia in Adults 1 1 Prognostic Markers and Models in Acute Lymphoblastic Leukemia 3Dieter Hoelzer 2 Acute Lymphoblastic Leukemia—Treatment and Outcomes in B-ALL 11Vijaya Raj Bhatt, Prajwal Dhakal, and Syed A. Abutalib 3 T Cell Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma 27Syed A. Abutalib and Daniel J. DeAngelo 4 Minimal Residual Disease in Acute Lymphoblastic Leukemia 51Caner Saygin, Sarah Monick, and Wendy Stock 5 Hematopoietic Transplantation and Cellular Therapy in Acute Lymphoblastic Leukemia 63Yael Morgenstern, Netanel A. Horowitz, and Jacob M. Rowe Part 2 Acute Myeloid Leukemia in Adults 81 6 Prognosis in Acute Myeloid Leukemia: Beyond Cytogenetics 83Caner Saygin and Lucy A. Godley 7 Young Adults with Acute Myeloid Leukemia 93Sangeetha Venugopal and Farhad Ravandi 8 Older Adults with Acute Myeloid Leukemia 103Mary-Elizabeth Percival and Elihu Estey 9 Acute Promyelocytic Leukemia 113Eytan M. Stein and Martin S. Tallman 10 Measurable Residual Disease in Acute Myeloid Leukemia 121Marie Bill and Hans Beier Ommen 11 Hematopoietic Cell Transplantation and Cellular Therapy in Acute Myeloid Leukemia 133Piyanuch Kongtim and Stefan O. Ciurea Part 3 Myelodysplastic Syndromes and Familial Myeloid Neoplasms 147 12 Diagnosis of Myelodysplastic Syndromes 149Jay Yang, Vijendra Singh, Ali Gabali, and Charles A. Schiffer 13 Treatment of Myelodysplastic Syndromes 165Rami S. Komrokji 14 Hematopoietic Cell Transplantation and Cellular Therapy in Myelodysplastic Syndromes 179Ibrahim Yakoub-Agha 15 Familial Myeloid Neoplasms—When to Suspect and What to Do? 191Ryan J. Stubbins, Amy M. Trottier , Simone Feurstein, and Lucy A. Godley Part 4 Myeloproliferative Neoplasms 211 16 Chronic Myeloid Leukemia: Chronic Phase Disease 213Jerald P. Radich 17 Chronic Myeloid Leukemia: Advance Phases of the Disease 221Michael J. Mauro 18 Chronic Myeloid Leukemia: Treatment Safety During Reproductive Age and Pregnancy 229Michael J. Mauro 19 Chronic Myeloid Leukemia: Cessation of Therapy 235Anand A. Patel and Richard A. Larson 20 Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia 243Jerald P. Radich 21 Polycythemia Vera 255Prithviraj Bose and Srdan Verstovsek 22 Essential Thrombocythemia 265Paola Guglielmelli and Alessandro Maria Vannucchi 23 Primary Myelofibrosis 275Douglas Tremblay, Sangeetha Venugopal, John Mascarenhas, and Ruben Mesa 24 Hematopoietic Cell Transplantation and Cellular Therapy in Primary and Post ET/PV Myelofibrosis 287Jerry Luo, Irum Khan, and Damiano Rondelli 25 Chronic Myelomonocytic Leukemia 305Mrinal M. Patnaik 26 Eosinophilic Myeloproliferative Disorders 315Jason Gotlib Part 5 Chronic Lymphocytic and Other Leukemias 331 27 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 333Jayastu Senapati, Nitin Jain, and Susan O'Brien 28 Hematopoietic Cell Transplantation and Cellular Therapy in Chronic Lymphocytic Leukemia 345Ajay Major, Michael R. Bishop, and Peter A. Riedell 29 Prolymphocytic Leukemia 357Dima El-Sharkawi and Claire Dearden 30 Hairy Cell Leukemia 371Justin M. Watts and Martin S. Tallman Part 6 Hodgkin Lymphoma 385 31 Classic Hodgkin Lymphoma 387Christopher R. D'Angelo, James O. Armitage, and Nancy L. Bartlett 32 Nodular Lymphocyte-Predominant Hodgkin Lymphoma 401Dennis A. Eichenauer 33 Hematopoietic Cell Transplantation and Cellular Therapy in Hodgkin Lymphoma 408Narendranath Epperla, Alex F. Herrera, and Matthew Mei Part 7 Non-Hodgkin's Lymphomas 417 34 Pitfalls in the Diagnosis of Non-Hodgkin's Lymphomas 419Carmen Barcena and Laurence de Leval 35 Follicular Lymphoma 435Danielle Wallace, Nancy Torres, and Carla Casulo 36 Mantle Cell Lymphoma 447Christina Poh and Stephen D. Smith 37 Marginal Zone Lymphoma 455Erin Mulvey, Wayne Tam, and Peter Martin 38 Hematopoietic Cell Transplantation and Cellular Therapy in Indolent Non-Hodgkin's Lymphomas 471Karthik Nath and Craig S. Sauter 39 Diffuse Large B Cell Lymphoma 485Alessia Castellino and Grzegorz S. Nowakowski 40 Hematopoietic Cell Transplantation and Cellular Therapy in Diffuse Large B Cell Lymphoma 499Shreya Desai, Syed Maaz Tariq, Arjun Patel, Istvan Redei, and Syed A. Abutalib 41 Primary Mediastinal Large B Cell Lymphoma 515Alessandro Broccoli and Pier Luigi Zinzani 42 Double-Hit and Double-Expressor Lymphomas 525David A. Russler-Germain and Brad S. Kahl 43 Transformed Lymphoma 539Frederique St-Pierre and Jane N. Winter 44 Burkitt Lymphoma 555Mark Roschewski and Wyndham Wilson 45 Primary and Secondary CNS Lymphomas 563Leon D. Kaulen, Nicholas A. Blondin, Fred H. Hochberg, and Joachim M. Baehring 46 HIV-Associated Lymphoma 579Elif Yilmaz and Kieron Dunleavy 47 Waldenström's Macroglobulinemia 589Morie A. Gertz 48 Primary Cutaneous Lymphomas 599Nicholas A. Trum, Jasmine Zain, Steven T. Rosen, and Christiane Querfeld 49 Mycosis Fungoides and Sézary Syndrome 635Robert Stuver, Alison Moskowitz, Sarah Noor, and Steven M. Horwitz 50 Peripheral T-Cell Lymphoma 647Avyakta Kallam and James O. Armitage Part 8 Plasma Cell Neoplasms and Related Disorders 659 51 Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma 661Francesco Maura, Dickran Kazandjian, and Ola Landgren 52 Risk Stratification Including Measurable Residual Disease in Multiple Myeloma 673Charalampos Charalampous and Shaji Kumar 53 Newly Diagnosed Multiple Myeloma: Transplant Eligible 687Sagar Lonial 54 Newly Diagnosed Multiple Myeloma: Transplant Ineligible 699Daniele Derudas and Claudio Cerchione 55 Relapsed/Refractory Multiple Myeloma 713Neha Korde and Saad Z. Usmani 56 Light-chain (AL) Amyloidosis 727Vaishali Sanchorawala 57 Bispecific T Cell Engager and Cell Based Immune Therapy in Multiple Myeloma 739Meera Mohan, Parameswaran Hari, and Saurabh Chhabra Part 9 Special Issues in Neoplastic Hematology and Cellular Therapy 751 58 Treatment of Lymphomas During Pregnancy 753Kieron Dunleavy, Emanuele Zucca, and Fedro A. Peccatori 59 Complications and Management of CAR T Cell Therapy 767Radowan A. Elnair and Matthew A. Lunning 60 Acute Graft-versus-Host Disease 781Aaron Etra, Uroosa Ibrahim, Jacques Azzi, and John E. Levine 61 Chronic Graft-versus-Host Disease 793Andrew Trunk and Daniel R. Couriel Index 809

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisMolecules Engineered Against Oncogenic Proteins and Cancer A comprehensive review of the latest molecular advances in cancer treatment Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, Molecules Engineered Against Oncogenic Proteins and Cancer documents the recent scientific advances that have transformed one of medicine's most challenging areascancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented. With a very well-known chemist as an author, Molecules Engineered Against Oncogenic Proteins and Cancer includes information on: Each molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action MuTable of ContentsPreface vii Chapter 1. Introduction 1 1.1 Types of Protein Kinases 1 1.2 Protein Kinase Domains 1 1.3 ATP-Binding Site 2 1.4 Types of Kinase Inhibitors 3 1.5 Brief History of Smallmolecule Kinase Inhibitors 5 1.6 Peak 12-Month Sales for Leading Kinase Inhibitors 7 1.7 Approved Kinase Inhibitors 7 Chapter 2. BCR-ABL Inhibitors 18 2.1 Imatinib* (1) 19 2.2 Nilotinib* (2) 24 2.3 Dasatinib* (3) 27 2.4 Bosutinib* (4) 30 2.5 Ponatinib* (5) 33 2.6 Olvermbatinib** (6) 37 2.7 Asciminib* (7) 38 Chapter 3. BTK Inhibitors 43 3.1 Ibrutinib* (8) 45 3.2 Acalabrutinib* (9) 51 3.3 Zanubrutinib* (10) 54 3.4 Tirabrutinib** (11) 57 3.5 Orelabrutinib** (12) 58 Chapter 4. EGFR/HER Family Inhibitors 59 4.1 Gefitinib* (13) 61 4.2 Erlotinib * (14) 67 4.3 Icotinib** (15) 72 4.4 Afatinib* (16) 74 4.5 Dacomitinib* (17) 77 4.6 Osimertinib* (18) 80 4.7 Mobocertinib* (19) 86 4.8 Lapatinib* (20) 90 4.9 Tucatinib* (21) 93 4.10 Neratinib* (22) 95 Chapter 5. VEGFR/Multikinase Inhibitors 97 5.1 Sorafenib* (23) 99 5.2 Regorafenib* (24) 104 5.3 Sunitinib* (25) 106 5.4 Pazopanib* (26) 112 5.5 Axitinib* (27) 114 5.6 Nintedanib* (28) 117 5.7 Apatinib** (29) 121 5.8 Lenvatinib* (30) 122 5.9 Tovozanib* (31) 125 Chapter 6. CDK4/6 Inhibitors 127 6.1 Palbociclib* (32) 129 6.2 Ribociclib*(33) 136 6.3 Abemaciclib* (34) 139 6.4 Trilaciclib* (35) 142 Chapter 7. JAK Inhibitors 144 7.1 Tofacitinib* (36) 147 7.2 Baricitinib* (37) 151 7.3 Peficitinib** (38) 153 7.4 Upadacitinib* (39) 158 7.5 Delgocitinib** (40) 161 7.6 Filgotinib** (41) 163 7.7 Abrocitinib* (42) 166 7.8 Ruxolitinib* (43) 170 7.9 Fedratinib* (44) 173 7.10 Pacritinib* (45) 175 7.11 Ritlecitinib # (46) 177 7.12 Brepocitinib # (47) 181 7.13 Ropsacitinib # (48) 184 Chapter 8. Allosteric TYK2 Inhibitors 187 8.1 Deucravacitinib* (49) 189 Chapter 9. ALK/multikinase Inhibitors 195 9.1 Crizotinib* (50) 197 9.2 Ceritinib* (51) 202 9.3 Alectinib* (52) 205 9.4 Brigatinib* (53) 207 9.5 Lorlatinib* (54) 210 Chapter 10. BRAF/Multikinase Inhibitors 214 10.1 Vemurafenib* (55) 216 10.2 Dabrafenib* (56) 222 10.3 Encorafenib* (57) 225 Chapter 11. MEK Inhibitors 227 11.1 Trametinib* (58) 228 11.2 Cobimetinib* (59) 232 11.3 Binimetinib* (60) 235 11.4 Selumetinib* (61) 237 Chapter 12. RET/Multikinase Inhibitors 240 12.1 Vandetanib* (62) 242 12.2 Cabozantinib* (63) 245 12.3 Selpercatinib* (64) 247 12.4 Pralsetinib* (65) 251 Chapter 13. FGFR Inhibitors 253 13.1 Erdafitinib* (66) 255 13.2 Pemigatinib* (67) 260 13.3 Infigratinib* (68) 263 13.4 Futibatinib* (69) 265 Chapter 14. PI3K Inhibitors 267 14.1 Alpelisib* (70) 269 14.2 Idelalisib* (71) 273 14.3 Duvelisib* (72) 277 14.4 Umbralisib* (73) 279 14.5 Copanlisib* (74) 281 Chapter 15. TRK/Multikinase Inhibitors 284 15.1 Larotrectinib* (75) 285 15.2 Entrectinib* (76) 288 15.3 Repotrectinib # (77) 291 Chapter 16. MET Inhibitors 294 16.1 Capmatinib* (78) 295 16.2 Tepotinib* (79) 297 Chapter 17. KIT/PDGFR/Multkinase Inhibitors 299 17.1 Avapritinib* (80) 301 17.2 Ripretinib* (81) 304 Chapter 18. FLT3 Inhibitors 306 18.1 Midostaurin* (82) 308 18.2 Gilteritinib* (83) 313 Chapter 19. mTOR Inhibitors 315 19.1 Sirolimus* and Analogs (84) 317 Chapter 20. Other Kinase Inhibitors 322 20.1 Netarsudil* (85) 324 20.2 Belumosudil* (86) 326 20.3 Fostamatinib* (87) 328 20.4 Pexidartinib* (88) 331 Chapter 21. KRAS Inhibitors 335 21.1 Sotorasib* (89) 337 21.2 Adagrasib* (90) 346 21.3 Jdq443 # (91) 350 Chapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases 353 22.1 High-quality Leads 353 22.2 Integrating Substructures from Different High Quality Leads or Established Inhibitors 355 22.3 Variation of Hinge-binding Nucleus 357 22.4 Macrocyclization 359 22.5 Fragment-based Approach 360 22.6 Covalent Inhibitors 361 22.7 Strategic Structural Modification of Prior Drugs 362 22.8 Exploiting a Specific Kinase Pocket to Optimize Selectivity 364 22.9 Solvent-exposed Appendages to Enhance Solubility and PK Properties 367 Chapter 23. Targeted Molecular Anticancer Therapies – Successes and Challenges 368 23.1 The Beginning 368 23.2 Further Developments 368 23.3 Biomarker-driven Drug Development 369 23.4 Mitigation of Drug Resistance 370 23.5 Miscellaneous Approaches 371 23.6 Discovery Chemistry 373 Appendix 1. First FDA Approvals by Year 374 Appendix 2. Kinase/KRAS Inhibitors in Development 375 Appendix 3. Visualization of Differentially Expressed Kinases in Cancer 378 Appendix 4. M & A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors 379 Appendix 5. Alphabetic List of Oncogenic Protein Inhibitors 380

Read more less

Book Synopsis* Helps health professionals to develop the communication skills needed to understand and assist those affected by cancer. * Discusses the social and psychological problems faced by people with cancer. * Gives detailed information about the qualities and skills needed to act as a helper.Trade Review‘This is an important book. It deals in a detailed, well-informed and approachable way with difficult issues. It offers much-needed help to health care workers who want to communicate sensitively with cancer patients. Enlivened by vignettes which illustrate each point, it is wise, humane and practical. I commend it strongly to everyone who needs to understand and talk about cancer to those who have the disease.’ Miles Little, Director, Centre for Values, Ethics and the Law in Medicine, University of Sydney ‘I welcome this book which should become the standard text for undergraduates and postgraduates in the humanization of modern medicine. At last we have two texts that can stand side by side, Communication in Cancer Care and C: Because Cowards Get Cancer Too [by John Diamond], the heads and tails of the humane practice of oncology.’ Michael Baum, Emeritus Professor of Surgery and Visiting Professor of Medical Humanities, University College LondonTable of Contents1. Cancer and Its Management. 2. The Social and Emotional Effects of Cancer. 3. The Individual Reality of Cancer. 4. Coping with Cancer. 5. The Helping Process. 6. Using Counselling Skills to Clarify Problems. 7. Problem Solving. 8. Professional Issues for Those Using Counselling Skills.

Read more less

Book SynopsisThe young ob/gyn patient presents unique problems different from the mature woman but which training often neglects. This user-friendly, practical book provides generous coverage of all aspects of pre-womanhood gynecology. Ranging from the commonest problems to the less common but urgent, it emphasizes diagnosis, special care and management throughout.Trade Review"Serves an important purpose ... .Conditions are well described with numerous explanatory diagrams and pictures and they include some illnesses that most trainees or even specialists may never have seen." (The Obstetrician & Gynaecologist, 2010) "A complete resource on the subject. ... It adds the perspective of young adult issues, which has not been addressed previously. I highly recommend this text to those in training and those in practice who see any pediatric, adolescent, or young adult women." (Fertility and Sterility, October 2009)Table of ContentsContributors vii Preface xi Foreword xiii Dedication xiv 1 Introduction 1Albert Altchek 2 Evaluation of the Newborn 12Albert Altchek 3 Early Diagnosis and Management of Atypical-Appearing Genitalia 14Genna W. Klein & Robert Rapaport 4 Diagnosis and Management of Congenital Adrenal Hyperplasia 25Karen Lin-Su, Saroj Nimkarn, & Maria I. New 5 Androgen Insensitivity and Gonadal Dysgenesis 36Claude Migeon & Kara Pappas 6 The Gynecologic Approach to the Child Adolescent and Young Adult 53Albert Altchek 7 Vulvovaginitis in the Child 60Albert Altchek 8 Vaginal Bleeding in the Child 81Albert Altchek 9 Ovarian Cysts in the Fetus Infant and Child 87Robert A. Cusick & Marc S. Arkovitz 10 Genital Trauma 97Diane F. Merritt 11 Sexual Abuse 111Nancy D. Kellogg 12 Adolescent Sexuality 124Don Sloan 13 Psychologic Aspects of Gynecologic Problems 131Albert Altchek 14 Approach to and Evaluation of the Adolescent Female 134Anne Nucci-Sack, Mary Rojas, Ivanya L Alpert, Elizabeth Lorde-Rollins, Mara Minguez, & Angela Diaz 15 Puberty in Girls 141Frank M. Biro 16 Delayed Puberty 145Janice L. Bacon 17 Primary and Secondary Amenorrhea 150Rachel J. Miller & Paula J. Adams Hillard 18 Precocious Puberty 159Peter A. Lee & Christopher P. Houk 19 Dysmenorrhea 171Albert Altchek 20 Pelvic Pain Endometriosis and the Role of the Gynecologist 174Farr R. Nezhat, Alireza A. Shamshirsaz, Gazi Yildirim, Ceana Nezhat, & Camran Nezhat 21 Management of Chronic Pelvic Pain in the Adolescent 194Kenneth A. Levey 22 Adolescent Anovulatory Dysfunctional Uterine Bleeding and Menorrhagia 204Albert Altchek 23 Bleeding Disorders in the Adolescent Female 210Aaron R. Rausen 24 Congenital Gynecologic Anomalies I – Rokitansky Syndrome (MRKH Syndrome) 215Albert Altchek 25 Congenital Anomalies II – “No Eponym Syndrome” and Diagnostic Problems 231Albert Altchek 26 Laparoscopy in the Pediatric and Adolescent Female 246Robert K. Zurawin 27 Disorders of the Young Breast 256Yasmin Jayasinghe & Patricia Simmons 28 Contraceptive Choices in Pediatric Adolescent and Young Adult Gynecology 265Albert George Thomas Jr 29 Contraception in Adolescence 299George Creatsas & Efthimios Deligeoroglou 30 Labor in the Adolescent 308Emanuel A. Friedman 31 The Polycystic Ovary Syndrome – Challenges and Opportunities in Adolescent Medicine 316Nathan Kase 32 Acute Abdominal and Pelvic Pain 340Jeremy T. Aidlen & Stephen E. Dolgin 33 Acute Gynecologic Pain 347Charles J. Ascher-Walsh & Michael Brodman 34 Vulva Disorders in Children 358Raymond H. Kaufman 35 Dermatology – The Dermatologist’s View of Diagnosis and Treatment of Vulvar Conditions 369Jennifer Aranda & K. Robin Carder 36 Management of Ovarian Cysts in the Adolescent and Young Adult 380Leslie R. Boyd, Khush Mittal, & John P. Curtin 37 Pediatric Gynecologic Cancer 390William Bradley III & Jamal Rahaman 38 Cervix Cytology Dysplasia and Human Papillomavirus 397Ali Mahdavi & Bradley J. Monk 39 Herpes Simplex Viruses Types 1 and 2 408David A. Baker 40 Sexually Transmitted Infections 415Rhoda Sperling 41 Imaging 427Sabah Servaes & Monica Epelman 42 Preservation of Fertility 445Michelle Tham & Alan B. Copperman 43 Where Law and Medicine Meet 449Rhea G. Friedman 44 Minors’ Rights to Reproductive Healthcare and Privacy 453Rhea G. Friedman 45 Human Papillomavirus Infection and Cervical Neoplasm Pathology in Adolescents 457Liane Deligdisch 46 Endometrial Pathology in Young Patients 462Liane Deligdisch 47 Ovarian Tumor Pathology in Children Adolescents and Young Women 467Liane Deligdisch 48 Gestational Trophoblastic Diseases Pathology in Adolescents and Young Adults 474Liane Deligdisch 49 Rhabdomyosarcoma of the Vagina and Cervix 480Frédérique Penault-Llorca, Hinde El Fatemi, & Florence Mishellany 50 Benign Ovarian Disorders 482Frédérique Penault-Llorca, Erika Rivera-Serrano, & Wassim Essamet 51 The History of Pediatric and Adolescent Gynecology in the United States 484Alvin F. Goldfarb 52 A History of the International Federation of Infantile and Juvenile Gynecology (FIGIJ) 487Irmi Rey-Stocker Index 493

Read more less

Book SynopsisIncludes case studies Covers evidence-based symptom management Encourages Allied Health Professionals to follow a patient-centred rehabilitation pathway Aims to facilitate the understanding and sharing of professional roles and to encourage holistic care at all stages and in all care settings Multiprofessional team of contributors.Table of ContentsSection 1: Introduction to Oncology and Palliative Care. Ch 1. Introduction to Oncology and Palliative Care. Geoff Sharpe and Paul A. Fenton. Ch 2. The Role of Rehabilitation in Oncology and Palliative Care. Jane Rankin and Jackie Gracey. Section 2: The Multi-professional Management of Specific Tumour Types. Ch 3. Breast Cancer and Associated Conditions. Melanie Lewis, Iona Davies and Jill Cooper. Ch 4. Lung Cancer and Associated Conditions. Debbie McKinney, Daniel Lowrie and Mandy Hamilton. Ch 5. Neurological Tumours and Associated Conditions. Joanne Carr, Kathy Thompson, Debbie Pearson, Paula Finlay and Helen White. Ch 6. Haematological Conditions. Jenny Miller, Phil Canning, Val Young, Sarah Taggart and Rachel Barrett. Ch 7. Head and Neck Cancer and Associated Conditions. Brenda Nugent, Lorraine Ashcroft, Gillian Lusty and Nicola Evans. Ch 8. Musculo-skeletal Tumours and Associated Conditions. Lena Richards, Merian Denning and Gemma Lindsell. Ch 9. Gastro-intestinal Tumours. Tessa Aston, Sallyanne McKinney, Jenny Miller and Heidi Williams. Ch 10. Genito-urinary Tumours. Doreen McClurg, Pippa McCabe and Karen Chambers. Section 3: Symptom Management. Ch 11. Lymphoedema Management. Rhian Davies and Sue Desborough. Ch 12. Cancer Related Fatigue Management. Catriona Ogilvy, Karen Livingstone and Gillian Prue. Ch 13. Pain Management. Karen Robb and Charlie Ewer-Smith. Ch 14. Dyspnoea/Breathlessness Management. Sarah Fisher and Daniel Lowrie. Ch 15. Maintaining Mental Health. Robin Davidson. Additional Contacts

Read more less

Book SynopsisColorectal cancer is a common cause of morbidity and mortality in which prevention, screening and early detection are vital. Beginning with the patient perspective and following the patient pathway, this new second edition covers epidemiology and prevention, screening programmes, decision support networks, the role of primary care, and supportive care for patients with colorectal cancer. The ABC of Colorectal Cancer provides the core knowledge on clinical genetics, diagnosis, imaging, therapy and surgery options and the latest evidence based guidelines for treating and managing colorectal cancer patients within the multidisciplinary team. Highly illustrated and accessible, it covers the full spectrum of the disease to provide the basis to make a real difference to clinical management. This is an invaluable practical guide for the non-specialist on all aspects of colorectal cancer, and is ideal for general practitioners, junior doctors, nurses and allied health professTrade Review“This short clinical review book of CRC strikes an excellent balance being both concise but with thorough and up-to-date coverage of the subject matter. The chapters based on their size, layout, and supporting figures are very approachable and I would suspect the book to be very useful to its intended audience of general practitioners and physicians in training. The text would seem to be most useful to those practicing clinical medicine, but could also serve as supplemental reading for those preparing for board-type examinations.” (Gastroenterology, 1 August 2012) “The information in the ABC of Colorectal Cancer is very well presented and the coverage is more than a GP would need in clinical practice.” (Australian Family Physician, 4 April 2012)Table of ContentsContributors vii Preface ix 1 The Patient Perspective 1 Kevin Bond 2 Epidemiology and Prevention 4 Peter Boyle, Patrick Mullie, Maria Paula Curado and David Zaridze 3 Pathways of Carcinogenesis 8 Michael Christie and Oliver Sieber 4 Clinical Genetics in the Management of Colon Cancer 13 Kai Ren Ong, Vicky Bowyer and Trevor Cole 5 Screening for Colorectal Cancer 19 Julietta Patnick and Wendy S. Atkin 6 Decision Support Networks 22 Matthew Kelly, Mark Austin and Sir Michael Brady 7 Pathology of Colorectal Cancer 26 Mohammad Ilyas 8 Imaging of Colorectal Cancer 31 Andrew Slater 9 The Role of Primary Care 36 Sue Wilson and Richard Hobbs 10 Radiotherapy for Rectal Cancer 40 Andrew Weaver 11 Surgical Interventions 44 Shazad Ashraf and Neil Mortensen 12 Adjuvant Therapy 48 Zenia Saridaki-Zoras and David Kerr 13 Treatment of Advanced Disease 52 David Watkins and David Cunningham 14 Innovative Treatment for Colorectal Cancer 58 Joanne L. Brady and David Kerr 15 Supportive Care for Patients with Colorectal Cancer 63 Pauline McCulloch and Annie Young 16 Follow-up 69 John Primrose Index 74

Read more less

Book SynopsisThis book comprehensively reviews the potential of focal therapy and discusses why the changing face of prostate cancer warrants a change in the way we treat men with the disease. It deals with the mechanisms by which disease can be localized within the gland and then the different technologies used for focal ablation.Trade Review“Whilst the book is not designed to represent a daily reference guide for the majority of the urological fraternity, it clearly does what it sets out to do; provide an up-to-date and comprehensive analysis of a treatment option that perhaps one day we will routinely consider alongside active surveillance and robotic surgery.” (Urology News, 1 November 2012)Fokaltherapie bedeutet Heilung und Organerhalt bei Männern mit lokal begrenztem Prostatakarzinom. Von einem internationalen Team führender Urologen, Onkologen, Radiologen und Pathologen geschrieben, bietet dieses Handbuch einen umfassenden evidenzbasierten Überblick über diese aufsehenerregende neue Therapieform.Table of ContentsContributor List, vii Preface, xi Section I Is there a role for Focal Therapy in Localised Prostate Cancer?, 1 1 The Rationale for Focal Therapy of Prostate Cancer, 3 Cole Davis, Matthew Cooperberg, and Peter R. Carroll 2 Factors That Affect Patients' Choice of Treatment, 11 Deb Feldman-Stewart and Michael D. Brundage 3 Histological Trends and the Index Lesion in Localized Prostate Cancer, 17 Vladimir Mouraviev, Thomas Wheeler, and Thomas J. Polascik 4 Selection Criteria for Prostate Cancer Focal Therapy, 29 Rajat K. Jain, Timothy K. Ito, and Samir S. Taneja Section II How can we accurately locate cancer within the gland?, 37 5 Localisation of Cancer within the Gland: Biopsy Strategies, 39 Winston E Barzell and Rodrigo Pinochet 6 Localisation of Cancer within the Gland: Ultrasound Imaging, 47 Ulrich Scheipers 7 Localization of Cancer within the Prostate: Dynamic Contrast-Enhanced MRI, 55 Philippe Puech, Anwar Padhani, Laurent Lemaitre, Nacim Betrouni, Pierre Colin, and Arnauld Villers 8 Localization of Cancer within the Gland: Diffusion-Weighted Magnetic Resonance Imaging of the Prostate, 66 Sophie F Riches, Nina Tunariu, and Nandita M deSouza 9 The future of Molecular and Biomolecular Imaging in Prostate Cancer, 75 Michael S. Gee and Mukesh G. Harisinghani Section III How can we create discrete tissue necrosis?, 85 10 Energies for Focal Ablation: Cryoablation, 87 John F. Ward 11 Focal Salvage Cryoablation in Recurrent Prostate Cancer, 98 Katsuto Shinohara 12 High-Intensity Focused Ultrasound, 106 Hashim Uddin Ahmed and Mark Emberton 13 Energies for Focal Ablation: Photodynamic Therapy, 114 Caroline M. Moore, Nimalan Arumainayagam and Mark Emberton 14 Focal Therapy for Prostate Cancer Using Radiation, 126 Irving Kaplan, Elizabeth Genega and Neil Rofsky 15 Image Registration and Fusion for Image-Guided Focal Ablation, 132 Dean Barratt and David Hawkes Section IV How can we determine the success of Focal Therapy? , 143 16 Determining Success of Focal Therapy: Biochemical and Biopsy Strategies, 145 Al Barqawi, Paul Maroni, and David Crawford 17 Determining Success of Focal Therapy: Imaging, 153 Alex Kirkham and Clare Allen 18 Evaluating Focal Therapy: Future Perspectives, 170 Hashim Uddin Ahmed and Mark Emberton Index, 179 Colour plate section can be found facing page 116

Read more less

Book SynopsisThis book is an excellent resource for nurses working in either a hospital or primary care Breast Cancer Care News This book would be really helpful to other breast cancer nurses and students about to embark on work in this field Journal of Community Nursing This comprehensive handbook is for nurses and other healthcare professionals involved in the care of people with breast cancer. It gives up-to-date evidence-based information and practical advice on nursing care throughout diagnosis, treatment, recovery and end-of-life care. Each chapter is written by an expert in the field. Topics include the anatomy of the breast, available treatments, complementary therapies, the psychological care of patients and their families, and the role of the specialist nurse. This book provides a well-balanced approach to all aspects of managing breast malignancy. The importance of writing from a nursing perspective is underlined so that the essenTrade Review“This book is essential reading for everyone working in breast cancer care in primary and secondary settings, from nursing students to breast care nurse specialists.” (Nursing Standard, 1 May 2012) "This is a valuable resource for all nurses working with breast cancer patients; it should become essential reading for those in training in the field, as well as for those with more experience." (Cancer Nursing Practice, 1 July 2011) "This is a well-written and well-organized resource for nurses caring for patients diagnosed with breast cancer. The organization is extremely user friendly and this update is justified." (Doody's, 12 August 2011) "This edition has updated guidelines and references to recent trials and changes to the UK screening program and a new chapter on survivorship issues and the long-term consequences and effects of recovery." (Booknews, 1 April 2011) Table of ContentsPreface vii Foreword by HRH The Prince of Wales ix Words of Encouragement for Nurses from Stella McCartney x Contributors xi Acknowledgements xiii 1 An Overview of the Breast and Breast Cancer 1 Elisabeth Grimsey 2 The Histopathology of Breast Cancer 19 Helen E. Froyd and Victoria Harmer 3 Genetic Factors in Breast Cancer 35 Audrey Ardern-Jones 4 Breast Screening 58 Ann-Marie Fretwell (previous contribution by Linda Lee) 5 Surgery for Breast Cancer 81 Victoria Harmer 6 Physiotherapy for Patients with Breast Cancer 103 Helen Macleod and Pauline Koelling 7 Breast Reconstruction 122 Nicola West 8 Chemotherapy as a Treatment for Breast Cancer 149 Elaine Lennan (previous contribution by Joan Klein née McCoy) 9 Radiotherapy as a Treatment for Breast Cancer 173 Karen Burnet 10 Endocrine Treatment for Breast Cancer 190 Deborah Fenlon and Kay Townsend 11 Lymphoedema and Breast Cancer 215 Mary Woods 12 Fungating Wounds 232 Victoria Harmer (previous contribution by Rachael King) 13 Advanced Disease 251 Elizabeth Sumner 14 Complementary and Alternative Therapies 282 Rosemary Lucey 15 Psychological Issues for the Patient with Breast Cancer 309 Jane Rogers and Mary Turner 16 Survivorship Issues 329 Carmel Sheppard 17 Specialist Nursing Roles: What Are the Challenges? 342 Emma Pennery Index 355

Read more less

Book SynopsisThe authors hope that their honest yet hopeful perspective will help all people with cancer and those who care about them.Trade ReviewAn authoritative manual of instructions... This book is highly recommended. -- M. G. Paregian Brief (at just 171 pages) but powerful, this straightforward book is both sobering and inspiring. Hopkins Medicine No matter how experienced a professional might be in dealing with patients with pancreatic cancer, it is refreshing to hear from the patient's perspective, reading how they navigate through the system before they land in our clinic and receive our care. Overall, I would recommend this book to all health professionals who care for patients with pancreatic cancer (both novice and seasoned), as well as those who are adjusting to a diagnosis of pancreatic cancer. -- Raymond Chan Cancer Forum This book is excellent. It is positive and compassionate... It would make a useful contribution to a library. Macmillan Cancer Support This book is a valuable source of intimate details about Pancreatic Disease and related problems... Highly recommended for the practicing instructions and frank discussions of personal and family preparation along with the current treatments that are available. M. G. ParegianTable of ContentsPreface1. The Gathering Clouds2. What Is Pancreatic Cancer and What Are Its Symptoms?3. The Fight Begins4. The Initial Treatment5. The Prospect of Death6. Balancing Hope and Truth7. Family and Friends8. Managing the Symptoms of Advanced Cancer9. A New Approach to Living10. Next Steps11. What We've Learned from Our ExperienceAppendix: Supplemental InformationNotesIndex

Read more less

Book SynopsisWith its unique combination of the latest research, expert advice, and compelling personal stories, this book gives previvors, survivors, and their family members the guidance they need to face the unique challenges of hereditary cancer.Trade ReviewA fine resource discussing the challenges of living in a high-risk body. Midwest Book Review An insightful and informative read. Nursing Times A top pick for any breast cancer collection. Midwest Book Review This book is an excellent resource for lay people trying to understand and deal with inherited breast and ovarian cancer. -- Judith Offman Journal of Family Planning and Reproductive HealthcareTable of ContentsForeword by Mark H. Greene, M.D.AcknowledgmentsIntroductionPart I: Understanding Cancer, Genetics, and Risk1. Breast and Ovarian Cancer BasicsMost Cancers Aren't HereditaryAn Introduction to Breast CancerAn Introduction to Ovarian CancerOther Hereditary Cancers2. A Peek Inside: Your Genes at WorkThe Evolution of Genetic Discovery: From Peas to BRCAYour Genetic ABCs . . . and a DMutations: Spelling Errors in Your DNA CookbookHow Mutations Lead to CancerWhat's So Special about BRCA?3. Defining RiskMaking Sense of StatisticsGetting Personal: Factors That Modify Your RiskIt's a Numbers Game4. Hereditary Cancer: What's Swimming in Your Gene Pool?Mutations from Mom or DadHidden Risk in the Family TreeHBOC and Other Hereditary Cancer SyndromesPlotting Your Genetic PedigreePart II: Assessing Your Risk5. Genetic CounselingThe Value of CounselingWhat to Expect from the ProcessWhy You Need an Expert to Unravel Your Genetic HistoryDeciding Who Should Test First6. Genetic Testing: Facing Your Hereditary HoroscopeWhich Test Is Right for You?Powerful, Yet ImperfectIssues for Survivors and Women in Treatment7. Decoding Your Test ResultsLife, Interrupted: It's PositiveGood News! You're a True NegativeWhen No Might Mean MaybeGenetic VariantsNow What? Implications for You and Your FamilyPart III: Managing Your Risk: Your DNA Doesn't Have to Be Your Destiny8. Early Detection StrategiesHigh-Risk Surveillance for Breast CancerHigh-Risk Surveillance for Ovarian CancerIs It Cancer?Screening for Other Hereditary Cancers9. ChemopreventionRisk-Reducing Medications for Breast CancerAlternatives under StudyChemoprevention for Ovarian Cancer10. Mastectomy for Risk Reduction and TreatmentReducing Cancer Risk by Removing the BreastsSkin-Sparing ProceduresTreating Breast Cancer with MastectomyWho Should Perform Your Surgery?Risks and Recovery11. Reconstruction: New Breasts after MastectomyDelaying Reconstruction to Complete Breast Cancer TreatmentLiving with a Flat ChestSaline and Silicone ImplantsOptions for Using Your Own TissueOptional Last Steps: Adding Nipples and AreolasGreat Expectations: Surgery and RecoveryChoosing the Right Surgeon12. Oophorectomy and Other Risk-Reducing Gynecologic SurgeriesOophorectomy ProceduresShould You Have a Hysterectomy Too?Oophorectomy, Mastectomy: Either, Neither, or Both?Issues for Breast Cancer Survivors13. Dealing with Menopause and Quality-of-Life IssuesSymptoms of Surgical MenopauseLong-Term Side EffectsShould You Take Hormones?Issues for Breast Cancer SurvivorsPart IV: Living with BRCA: Issues and Answers14. Managing Lifestyle ChoicesThe Three-Legged Stool: Nutrition, Weight, and Physical ActivityAlcohol: An Unwise ChoiceOther Lifestyle Risk Factors15. Sharing Information with Friends, Family, and CoworkersSharing Risk and Genetic Testing Information with FamilyIssues for Spouses, Partners, and People You DateWhat Should You Tell Employers and Coworkers?16. Young and at High RiskShould You Consider Testing Now?Diagnostic DifficultiesDealing with a Diagnosis before MenopausePlanning Your Family, Preserving Your FertilityOophorectomy in Young WomenSorting through Emotions17. How BRCA Affects MenMen Get Breast Cancer TooHigh Risk for Prostate CancerOther BRCA-Related Cancers18. Diagnosis: Hereditary CancerHow Important Is a Second Opinion?Treating Hereditary CancersMaking Breast Cancer Treatment DecisionsOvarian Cancer IssuesThe Importance of Clinical Trials19. Putting the Pieces Together to Make Difficult DecisionsStart at the Beginning: Should You Be Tested?Making Decisions to Reduce Your RiskMaking Decisions about TreatmentFrom Confused to Clear in Fifteen StepsNotesIndex

Read more less

Book SynopsisWherever they are in their own journey with cancer, readers will find here a personal, practical, and powerful guide to recovery.Trade ReviewThe key to the book's success, is the mixture of compassionate wisdom and intelligent advice derived from the author's unique perspective. American Reference Books Annual It just has everything in this book and the author is meticulous to detail... Although written for a US market this book is extremely valuable for the UK healthcare setting too. The book is well referenced at the end of each chapter. Nursing TimesTable of ContentsAcknowledgments1. Get Your Life Back on Track2. Understand Physical Healing3. Dare to Dream Again4. Prioritize What You Do and Pace Yourself5. Seek Help from Conventional Medicine6. Explore Eastern and Other Medical Systems7. Dance, Skip, and Walk: Exercise Your Way Back to Health8. Nourish Your Body9. Fight Fatigue10. Ease Your Pain11. Monitor Your Mood12. Tap into Your Spirituality13. Love and Be Loved14. Surmount Setbacks15. Look What's on the HorizonAfterwordAppendixIndex

Read more less